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1. Introduction 
During eukaryotic cell division, in order for each daughter cell to inherit one and 
only one copy of each chromosome, the mother cell must replicate its chromosomes 
exactly once in the synthetic phase, and then must separate the replicated 
chromosomes evenly at the end of the mitotic phase to the two daughter cells. 
Defects in the coordination of chromosome replication and chromosome 
segregation can have severe consequences leading to genetic instability and 
aneuploidy, and eventually fostering tumour malignancy.1-3  
To ensure faithful transmission of chromosomes during cell division, eukaryotic 
cells have evolved cellular regulatory mechanisms termed cell cycle checkpoints.4 
The checkpoints prevent or delay cell cycle progression if certain cellular processes 
or proteins are disrupted, to gain time to repair the damage before cell division 
occurs. When the damage is irreparable, the cell undergoes apoptosis through the 
triggering of specific biochemical pathways.5 However, cancer cells often harbor 
defective cell cycle checkpoints allowing for uncontrolled cell proliferation, even 
when cell division does not occur properly.  
Therefore, effective cancer treatment can be achieved by drugs that target certain 
processes or proteins impinging on the cell cycle machinery.6 In particular, chemical 
compounds that target microtubules and inhibit the normal function of the mitotic 
spindle, have proven to be one of the best classes of cancer chemotherapeutic drugs 
available to date.7 Among these, paclitaxel and vinblastine are clinically used to treat 
different human tumours, e.g. ovarian, mammary, lung, and haematological cancers.  
However, restrictions due to toxicity, drug resistance, complex formulations and 
limited bioavailability highlight the need for novel tubulin inhibitors. 
2. Microtubules and tubulin 
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2. Microtubules and tubulin 
Microtubules (MTs), the dynamic pipe-like protein composed of α,β-
heterodimers, are essential cytoskeletal polymers and are present in all eukaryotes, 
affecting cell shape, cell transport, cell motility, and cell division. MTs are long, 
hollow structures with 5 nm walls surrounding a cavity, usually with internal and 
external diameters of ~15 and ~25 nm, respectively. They are made up of two 
globular protein subunits, α- and β-tubulin (TB). The α- and β-subunits form 
heterodimers which aggregate in a head to tail arrangement to form long tubes made 
up of stacked rings with each ring usually containing 13 subunits, which is know as 
protofilament. After an induction period, the protofilaments group together to form a 
C-shaped protein sheet, which then curl around to give a pipe-like structure known 
as microtubule (Figure 1).7 
α- and β-TB, each with a molecular weight of about 50 kDa, are regarded as the 
main components of MTs. There are six isotypes of each α- and β-TB in human 
cells, showing tissue-, cell- and tumor-specific patterns of expression as well as 
differences in protein binding.8 Both α- and β-TB bind a guanine nucleotide, which 
is non-exchangeable when bound in the α-subunit (N-site) and exchangeable when 
bound to the β-subunit (E-site).7  
The structures of α- and β-TB are basically identical: each monomer is formed by 
a core of two β-sheets surrounded by α-helices. The monomer structure is very 
compact, but can be divided into three functional domains: the N-terminal nucleotide 
binding domain (residues 1 to 205), an intermediate domain (residues 206 to 384), 
and the C-terminal domain (residues 385 to the C-terminus). 
TB dimer structure has been solved at 3.7 Å by electron crystallography of the 
two-dimensional crystalline sheets of TB that form in the presence of zinc ions 
(Figure 2).9,10 
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Figure 1. Microtubule components. 
 
TB(α1β1α2β2)/stathmin-like domain complex has been also solved by X-ray 
crystallography at 3.5 Å resolution (Figure 3).11,12 Stathmin is a 17 kDa ubiquitous 
cytosolic phosphoprotein, recognized as a MT destabilizing factor.  
By contrast with the TB in zinc sheets, the TB(α1β1α2β2)/stathmin-like domain 
complex appears curved. MTs are polar polymers that bind to and hydrolyze GTP, 
and show distinct (+, plus) and (−, minus) ends. The structural polarity of MTs is 
created by the regular, parallel orientation of all of their subunits. The plus end is 
capable of rapid growth and is kinetically more dynamic than the minus end, which 
tends to lose subunits if not stabilized. Although both ends alternately grow or 
shorten, net growing occurs at the plus end and net shortening at the minus end.13  
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Figure 2. Ribbon diagram of the electron crystallography structure of zinc-induced αβ-tubulin sheets 
(α-tubulin in cyan, β-tubulin in purple, GDP in green, GTP in yellow; PDB code: 1JFF10). 
2. Microtubules and tubulin 
 5
 
Figure 3. Ribbon diagram of the X-ray structure of tubulin(α1β1α2β2)/ stathmin-like domain complex 
(α1-, α2-tubulin in cyan, β1-, β2-tubulin in purple, GDP in green, GTP in yellow, stathmin-like 
domain in gray; PDB code: 1SA012). 
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The plus ends of the MTs are often free in the cytoplasm or located near the 
plasma membrane, whereas the slow-growing or minus ends of the MTs are 
frequently associated at a single site in the cell named the microtubule organizing 
center (MTOC) or centrosome.14 MTOC represents the specific location from which 
MTs are nucleated. A major component of the MTOC is γ-TB,15 which shows a 28-
35% homology with α- and β-TB and is expressed in lower amounts than these latter 
isoforms. A number of γ-TB ring complexes (γ-TuRC) have been isolated and 
behave as impressive in vitro nucleators of MT growth (Figure 4).16-18 
 
 
 
Figure 4. A: Schematic diagram of a microtubule. B: Model for the structure of the γ-tubulin ring 
complex (γ-TuRC). C: Microtubule nucleation by the γ-TuRC.  
 
In interphase the MTOC or centrosome is normally located to one side of the 
nucleus, close to the outer surface of the nuclear envelope, and embedded in the 
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centrosome are the centrioles, a pair of cylindrical structures arranged at right angles 
to each other in an L-shaped configuration.  
Polymerization of MTs occurs by a nucleation-elongation mechanism in which 
the formation of a short MT nucleus is followed by elongation of the MT at its ends 
by reversible, non-covalent addition of α/β-TB dimers. 
In 1984, Mitchison and Kirschner proposed the dynamic instability model of MT 
assembly, in which individual MTs exist either in an elongation state or a rapidly 
shortening state, with abrupt and apparently random transitions between these two 
states.19,20 Several studies performed in vitro, using purified TB,21,22 or in living 
cells,23 have confirmed this mechanism of MT assembly/disassembly.  
MTs are thus governed by an intrinsic property involving repetitive spurts of 
shortening from their plus ends, followed by periods of polymerization. This non-
equilibrium behavior is based on the binding and hydrolysis of GTP at E-site in β-
TB. Only dimers that have GTP in their E-site can polymerize. This nucleotide is 
then hydrolyzed and becomes non-exchangeable. The GTP cap model proposes that 
the GDP-TB core of MT is stabilized at the plus end by a layer of GTP-TB subunits 
that may act to maintain association between protofilaments.24,25 When this cap is 
stochastically lost, the protofilaments peel outward and the MT rapidly 
depolymerizes. Although both MT ends can either grow or shorten, the changes in 
length at the plus end are much greater than at the minus end (Figure 5). MTs exhibit 
another important dynamic behavior called treadmilling or flux. It corresponds to a 
polymer mass steady state resulting from the net growth at one MT end and the net 
shortening at the opposite end.26 In other words, treadmilling is a process by which 
TB subunits continuously flux from one end of the polymer to the other, due to net 
differences in the critical subunit concentrations at the opposite MT ends.  
Figure 6 remarks the different movement of the TB dimer involved into the 
dynamic instability and the treadmilling. Both dynamic instability and treadmilling 
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 8
can be produced as distinct phenomena in vitro using purified TB, and they have 
also been observed in living cells.26,27 
 
 
 
Figure 5. Microtubule polymerization dynamics and GTP cap.  
 
In living cells, MT dynamics are regulated both spatially and temporally. In fact, 
MTs interact with an impressive number of binding proteins, and cellular MT 
dynamics are thus the result of the combined effect of stabilizing and destabilizing 
factors. MT assembly/disassembly is firstly controlled by a balance between MT 
stabilizing and destabilizing proteins that bind along the MTs.28 Stabilizing proteins 
include a large group of so-called microtubule associated proteins or MAPs,29 that 
stabilize MTs against disassembly. 
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Figure 6. Different movement of the tubulin heterodimer involved into the dynamic instability (A) 
and the treadmilling (B). 
 
MAPs are targets for protein kinases, including p34cdc2 kinase (cyclindependent 
kinase 1, CDK1), which control changes in MT dynamic properties at the G2 to M 
phase transition of the cell cycle. Phosphorylation of MAPs increases during mitosis 
and reduces their affinity for MTs, thereby reducing their ability to promote MT 
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polymerization.30,31 Major MAPs include MAP1, MAP2, MAP4 and tau. MAP4 is 
the most abundant and ubiquitous MAP in non neuronal cells that stabilizes MTs.32 
MAP4 phosphorylation by the cyclin B1/p34cdc2 complex decreases its MT 
stabilizing ability at mitosis.31 The destabilizing factors are a growing family of 
proteins that include Oncoprotein 18 (Op18)/Stathmin, Xenopus kinesin central 
motor 1 (XKCM1), and katanin.28 Op18/stathmin is a small protein (19 kDa), highly 
expressed in leukemic cells, that physically interacts with TB dimers and increases 
the catastrophe rate of MTs.33,34 Phosphorylation of Op18/stathmin by p34cdc2 
kinase increases the MT catastrophe rate at mitosis.35,36 XKCM1 is a kinesin-related 
protein that promotes MT depolymerization during mitotic spindle assembly, and 
regulates MT dynamics during mitotic spindle assembly.37 
Other MT binding proteins called motor proteins are critical for MT function. 
Motor proteins bind to MTs and use the energy derived from ATP hydrolysis to 
move steadily along it. They can carry membrane-enclosed organelles, such as 
mitochondria, Golgi stacks, or secretory vesicles, to their appropriate locations in the 
cell, and cause cytoskeletal filaments to slide against each other, a crucial process in 
cell division. Two major classes of MT dependent motor proteins are collectively 
grouped as kinesins and dyneins, which in turn comprise a great number of 
proteins.38 Most of the kinesin superfamily proteins (KIFs) have specific roles in 
mitotic spindle formation and chromosome separation during cell division as well as 
in transport, and walk toward the plus end of the MT. However, C-terminal motor 
domain-type KIFs (KIFCs), including KIFC3, travel towards the minus end of MTs. 
Dyneins are a family of minus end-directed MT motor proteins, less diverse than 
kinesins, and play an important role for vesicle trafficking as well as for the 
appropriate localization of intracellular organelles. Kinesins and dyneins generally 
move in opposite directions along MTs, and thereby control bi-directional vesicle 
transport.38 
3. Microtubule interfering agents in cancer chemotherapy 
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3. Microtubule interfering agents in cancer chemotherapy 
The crucial role of MTs in vital cellular functions for tumour cells, including 
mitosis, motility and cell-cell contacts, has made of MTs a valuable target for cancer 
chemotherapy. A large number of chemically diverse compounds, many of which 
are derived from natural products, are able to bind TB or MTs and inhibit 
proliferation by acting on the mitotic spindle. Some of these compounds (vinca 
alkaloids, colchicine) inhibit MT polymerization, whereas others (taxanes) stabilize 
MTs. But, although these compounds exert opposite effects on MTs, both types of 
MT interfering agents (MIAs) share the common property of suppressing MT 
dynamics and thereby MT function, leading to the disruption of the mitotic spindle 
function and blocking cell cycle progression at the transition from 
prometaphase/metaphase to anaphase.39 This mitotic arrest is the major action of the 
distinct MIAs. 
MT damaging agents, also named “spindle poisons” due to their inhibitory action 
on mitotic spindle, represent an important class of anticancer drugs. Agents that 
target MTs have been used in the treatment of cancer for over 35 years. More 
recently developed MT active compounds have demonstrated effectiveness against a 
broad spectrum of tumour. Because MTs are integral and crucial components of the 
mitotic spindle, interference with MT dynamics results in metaphase arrest in 
dividing cells. However, because MTs are also involved in a large number of other 
cellular functions, including chemotaxis, membrane and cellular scaffolding, 
intracellular transport, secretory processes and transmission of receptor signaling, 
MT interfering compounds may affect both neoplastic and nonmalignant cells in 
interphase, in addition to the mitotic phases of the cell cycle. This essential lack of 
selectivity towards tumour cells leads to a number of toxic side effects and to a 
rather low therapeutic index, for most of the MT interfering compounds.  
All MIAs induce mitotic arrest followed by apoptosis. They block the cell cycle 
at M phase, mainly due to damage on the mitotic spindle, resulting in activation of 
3. Microtubule interfering agents in cancer chemotherapy 
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the mitotic spindle assembly checkpoint. Failure to proceed through the cell cycle is 
responsible for the activation of apoptosis. How disruption of MT dynamics leads to 
apoptosis is now being explored, but evidence that diffusible factors may be released 
as the result of changes in MT polymerization is consistent with the hypothesized 
role of MTs in sequestering signals.40 Release or activation of these sequestered 
elements could allow them to reach their targets and to mount a response, including 
apoptosis. Although several lines of evidence show important links between 
cytoskeletal integrity and apoptosis regulation, the molecular mechanisms for these 
links are likely to be numerous. Because MIAs promote apoptosis mainly through 
their inhibitory actions on the mitotic spindle, the molecular mechanisms underlying 
the link between MT interference and the onset of apoptosis is suggested to be 
essentially similar among these agents. Thus, although there are some differences 
among the distinct MT active compounds concerning specific alterations in certain 
signaling pathways,41 the major signaling route underlying their cytotoxic action 
seems to be similar to all of them through a mitotic spindle damage-dependent 
process. In addition, MIAs can promote a number of effects on the spindle poles or 
centrosomes, including abnormal centriole structure,42 centrosome fragmentation,43 
and inappropriate centrosome duplication.44 
Most of the current antitumor drugs target a molecule or cell process present in 
both tumour and normal cells, leading to a predicted and marked non selective 
action. However, certain properties acquired by the tumour cells make them 
sometimes more susceptible to be targeted. In this regard, although the MIA target is 
present in both tumour and normal cells, and thereby a non selective behaviour 
could be foreseen for these antitumor drugs, certain properties of tumour cells make 
them more susceptible for the attack of these agents, such as: (a) a higher capacity to 
cell proliferation in some tumours giving more opportunities to the MT active drugs 
to attack on mitotic spindles; and (b) a high percentage of p53 mutations in tumour 
cells that favors the action of at least some MIAs.45,46  
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MIAs act by binding to various sites on the TB dimer and at different positions 
within the MT and can be classified into three major categories based on their 
respective TB binding domains which include paclitaxel site binding agents, 
colchicine site binding agents, and vinca alkaloid site binding agents. 
 
3.1 Paclitaxel site binding agents 
Taxoids, a promising group of antimitotic anticancer agents, have a unique 
mechanism of action, binding mainly to a domain distinct from those of colchicine 
and vinca alkaloids and inhibiting the depolymerization of polymerized TB.47 The 
first marketed taxoid drug was paclitaxel (1), which was isolated from the bark of 
the Pacific yew tree Taxus brevifolia.48 This endangered tree produces low yields of 
paclitaxel that cannot satisfy the increasing demand. Later paclitaxel was also 
isolated from hazelnut trees (leaves, twigs, and nuts) and the fungi living on these 
trees but the concentration is only about 10% of the concentration in yew trees. This 
drug has now been semisynthesized from baccatin III (2), an analogue of paclitaxel 
without the C13 side chain, which is isolated from Taxus baccata,49 or fully 
synthesized50 and at present is used extensively in the treatment of breast and 
ovarian cancers. It is also used for skin, lung, and head and neck carcinomas.51 
Chemistry of this diterpinoid is very complex comprising of an unusual oxetane 
ring at C4-C5 and an isoserine side chain at C13 position. Although some 
therapeutically active paclitaxel analogues modified at C10 and C2 have been 
developed as advanced second generation taxoids,52 structural variations along the 
upper part at C6-C12 appear to have less impact on the bioactivity. The lower part, 
on the other hand, comprising of C14 and C1-C5 appears to be a region which is 
crucial to the activity. Most changes to the C and D rings, including opening of the 
oxetane ring, lead to loss of activity,53 although some examples of C ring opened 
compounds that retain significant activity have been developed.54 
3. Microtubule interfering agents in cancer chemotherapy 
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Extensive structure activity relationship (SAR) studies have provided insight into 
the structural determinants that are important for the activity of paclitaxel. It is now 
established that the A ring side chain at C13 with a C2'-OH, the C2 benzoyl group 
and an intact oxetane ring at C4-C5 are essential for both cytotoxicity and 
stabilization of MTs.55,56 The oxetane ring is a unique feature of paclitaxel and 
analogues prepared with an opened oxetane ring have a greatly reduced activity.53 
The C4 acetyl group does not appear to play a significant role in the biological 
activity but may contribute to the defined conformation of the molecule. The C1-OH 
group makes a significant contribution to the overall bioactivity.53 The OH group at 
C7 is not essential for biological activity.56 
The structure of the TB/paclitaxel complex has been solved at 3.5 Å by electron 
crystallography,10 showing that paclitaxel binds β-TB within the lumen of MT 
(Figure 7). A considerable number of residues, mostly in the second domain of β-TB, 
are involved in direct contact with paclitaxel. 
To date, more than 350 taxoids have been isolated from Taxus species, developed 
and characterized,57,58 but very few are found to be potent cytotoxics. Poor water 
solubility and a very low yield of paclitaxel motivated researchers to design and 
develop new analogues of paclitaxel that are more cytotoxic. 
Docetaxol (3),59 with minimal structural modifications at C13 side chain and C10 
substitution showed more water solubility and more potency than paclitaxel, 
whereas baccatin, without C13 side chain, has no significant cytotoxicity. The C13 
side chain could be a target for developing new analogues.  
2-Debenzoyl-2-(m-azidobenzoyl)-paclitaxel (4), a C2 modified analogue, was 
found to be more potent (IC50 = 0.31 ± 0.01 μM) than paclitaxel (IC50 = 0.42 ± 0.03 
μM).60 14β-Hydroxy-10-deacetylbaccatin III (14β-OHDAB, 5), first isolated from 
the needles of Himalayan yew tree, has a higher water solubility.61  
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Figure 7. Ribbon diagram of the crystallography structure of αβ-tubulin/paclitaxel complex (α-
tubulin in cyan, β-tubulin in purple, GDP in green, GTP in yellow, paclitaxel in white; PDB code: 
1JFF10). 
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New taxoids derived from it may show improved water solubility, bioavailability, 
and reduced hypersensitivity.52 Synthesis of second generation taxoids by 
appropriate modification at C3', C2 and acylation at C10, produces taxoids62-64 with 
extremely high potency against drug resistant cancer cells and compound 6 showed 
two orders of magnitude better activity than those of paclitaxel and docetaxel.52 
To evaluate the importance of the taxane core of taxoids, simplified compounds 
typified by compound 7 with the key pharmacophore properties of paclitaxel, 
phenylisoserine and an oxetane ring, were synthesised but none showed promising 
TB inhibitory activity.  
This finding justifies the necessity of the diterpene ring.65 Novel 7-deoxy-9-
dihydropaclitaxel analogues, typified by compound 8, have been synthesised and 
found to have potent selectivity against human liver cancer cells.66 
Synthesis of a new class of borneol esters 9 that might be considered as analogues 
of paclitaxel has been reported, but these compounds showed reduced cytotoxic 
activity.67 Design of new taxanes has been directed towards solving the limitations 
of both solubility and resistance.  
The paclitaxel ester of malic acid 10 has demonstrated improved solubility and 
enhanced in vivo antitumor activity against P388 murine leukemia indicating a 
higher therapeutic index than paclitaxel.68 
Chemical structures of compounds discussed in this section are presented in 
Figure 8. 
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3.2 Colchicine site binding agents 
Colchicine (11), a well known alkaloid, obtained from Colchicum autumnale and 
other plants, a classic TB binding agent,69 is used in the treatment of gout, familial 
Mediterranean fever and liver cirrhosis.70 Colchicine binds to soluble TB and forms 
a TB/colchicine complex, followed by ligand-induced conformational changes in 
both TB and colchicine itself and thereby causes the MT spindle to disassemble in 
the metaphase of mitosis. Experimental data showed that colchicine binds to β-TB at 
its interface with α-TB,71 resulting in inhibition of TB polymerization. This binding 
mode was recently confirmed by the determination of a 3.58 Å X-ray structure of 
TB complexed with N-deacetyl-N-(2-mercaptoacetyl)colchicine (DAMA-colchicine), 
which is a close structural analogue of colchicine (Figure 9).12 The binding site(s) of 
colchicine on TB have been extensively studied.72,73 It has been reported that the β-
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subunit of TB is involved in colchicine binding, with the A ring of colchicine lying 
between Cys-354 and Cys-239 and C ring lying between the peptide region 
containing Cys-239 and the amino terminal β-TB sequence and region β:1-36.74,75 
The seven membered B ring and the C7 side chain are not believed to be crucial 
for TB binding but may affect the conformation of colchinoids and their TB binding 
properties.76,77 The trimethoxyphenyl group of the A ring of colchicine serves as a 
complex stabilizing anchor on TB in the inhibition of MTs assembly and is essential 
for its activity. An important structural feature of colchicine is the α-
methoxytropolone, which constitutes the C ring portion of the colchicine molecule. 
The tropolone ring and the C9 or C10 substitutes have been implicated in several 
aspects of the ligand-TB binding mechanism.78 This drug has also been reported to 
bind to a second, lower affinity site on TB in a reversible manner.79 Although 
colchicine is one of the oldest antimitotic drug, its toxicity is similar to its activity. 
Hundreds of colchicine analogues have been prepared in past decades, including 
compounds isolated from natural sources, partially synthesized from colchicine, and 
de novo synthesized. Some have been used clinically as antitumor agents, having 
less toxicity than colchicine. Most modified colchicine analogues share a common 
binding site on tubulin, common mechanisms for TB binding and similar 
pharmacological actions. 
Colchicone (12), a non-nitrogen containing natural product isolated from 
Colchicum richterii and synthesised by Banwell et al. has been reported to show an 
inhibitory effect on TB polymerization.80,81 Compound 13, a bicyclic analogue of 
colchicine binds rapidly and reversibly to colchicine binding site of TB, inhibits 
MTs assemble and promotes apoptosis in human leukemic cells. This drug produces 
reversible effects on MT disassembly, G2/M phase arrest, more water solubility and 
has lower toxicity than colchicine.82 
Among colchicine analogues, thiocolchicine (14) has shown more activity than 
the parent colchicines.  
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Figure 9. Ribbon diagram of the X-ray structure of tubulin(α1β1α2β2)/stathmin-like domain/DAMA-
colchicine complex (α1-, α2-tubulin in cyan, β1-, β2-tubulin in purple, GDP in green, GTP in yellow, 
stathmin-like domain in gray, DAMA-colchicine in white; PDB code: 1SA012). 
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Most natural analogues are modified in the C7 side chain substituents except 
allocolchicine (15), with an aromatic 6-member ring and a COOCH3 substituent at 
C10, and cornigerine (16) with an OCH3 substituent at C10, which have both been 
obtained from Colchicum cornigerum.83 Allocolcichine which has also been isolated 
from Colchicum autumnale and N-acetylcolchinol O-methylether, a semisynthetic 
analogue obtained by reaction of colchicine with hydrogen peroxide, are both more 
potent inhibitors than colchicine.84,85  
Podophyllotoxin (17) and its related analogues were isolated from Podophyllum 
peltatum and related species. Podophyllotoxin and its related analogues (18, 19) bind 
to TB protein at the colchicine site and competitively inhibit colchicine binding to 
TB although a recent computer modelling study suggested incomplete overlap of the 
colchicine and podophyllotoxin binding site(s).86  
Etoposide (20) is a potent topoisomerase II (an enzyme involved in the folding 
and unfolding of DNA during cell replication) inhibitor but a weak TB inhibitor.87  
It has also been reported that their predominant function is inhibiting 
topoisomerase II rather than a microtubular interaction.88 Etoposide is currently used 
in the treatment of small cell lung, testicular and malignant lymphoid cancers, 
among others.89 It is also used in combination chemotherapy. Teniposide (21) 
appears to be a less useful clinical agent though it is undergoing trials in 
combination therapy for the treatment of metastatic brain tumors.90 Combretastatin 
A-4 (22), an antineoplastic agent isolated from Combretum caffrum,91 is a simple 
compound that show antimitotic effects by interacting with the colchicine binding 
site of TB. Combretastatin A-4 is one of the most potent inhibitors of colchicine 
binding presently known.92 Naturally occurring and synthetic combretastatin and its 
analogues (23, 24) were identified as antimitotic agents binding to colchicine 
binding sites.91 Combretastatin A-4, the most potent cancer cell growth inhibitor of 
the series,93 is not recognised by the multi-drug resistance (MDR) pump, a cellular 
pump which rapidly ejects foreign molecules including many anticancer drugs.94  
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It has also been reported that this compound can inhibit angiogenesis, a process 
essential for tumour growth.95 Combretastatin A-4 itself is insoluble and several 
attempts have been made to produce an active water soluble derivative.96,97 The most 
effective is the disodium phosphate salt 25 (>20 mg/ml) and is the form of 
combretastatin A-4 presently in phase II clinical trials.98,99 SAR of combretastatin A-
4 led to the discovery of the potent cancer cell growth inhibitor phenstatin (26) and 
hydroxyphenstatin (27), which showed remarkable antineoplastic activity by 
inhibiting TB polymerization. 
Chemical structures of compounds discussed in this section are presented in 
Figure 10. 
 
3.3 Vinca alkaloid site binding agents 
Vinca alkaloids, vincristine (28) and vinblastine (29), are the most useful class of 
antimitotic anticancer agents for the treatment of leukemias, lymphomas and some 
solid tumours.100 These agents, isolated from Catharanthus roseus, are widely used 
as anticancer drugs.101,102 Vinca alkaloids prevent MT assembly by binding to TB at 
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a site distinct from colchicine and by blocking the region involved in heterodimer 
attachment.100 Vinca alkaloids bind to TB very close to GTP site that is located at 
both the α and β-subunits with primary sequences around α-339 and β-390 
residues.103 The structure of vinblastine bound to the TB/stathmin-like 
domain/vinblastine complex was determined at 4.1 Å resolution by X-ray diffraction 
(Figure 11).104 Unlike colchicine, vinca alkaloids bind to TB rapidly, reversibly and 
temperature independently.73,83 The SAR, pharmacology and clinical uses of vinca 
alkaloids have been reviewed.105 After the establishment of vinca alkaloids as 
promising anticancer agents, efforts have been made to develop new congeners that 
are more effective, have less side effects and have a broad spectrum of antitumor 
activity. The basic structure of vinca alkaloids is composed of a catharenthine 
moiety and vindoline nucleus and these alone cannot inhibit MT assembly.100 Most 
of the semisynthetic or totally synthetic vinca alkaloids drugs have been developed 
by the modification of C4, C23, C3' and C4' position of parent vinca alkaloids.105 
Vindesine (30), the first semisynthetic vinca alkaloid, was developed by changing 
the C23 acetyl group in vinblastine to an amide.106 Modifying the vindoline moiety 
with L-tryptophane at C23 led to the development of vintripole (31).107 
Vinxaltin (32) is in phase II clinical trial for advanced breast cancer showing an 
excellent antitumour profile.107 Another semisynthetic compound vinorelbine (33) 
showed promising activity against breast cancer108 and is in clinical trial for the 
treatment of other types of tumours.109 This drug exihibited superior antimitotic 
activity over others with lower reversible neurotoxicity.  
Further modifications in vinorelbine led to the discovery of vinflunine (34) which 
showed significantly superior anticancer activity in vivo as compared to 
vinorelbine.110  
Chemical structures of compounds discussed in this section are presented in 
Figure 12. 
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Figure 11 Ribbon diagram of the X-ray structure of tubulin(α1β1α2β2)/stathmin-like 
domain/vinblastine complex (α1-, α2-tubulin in cyan, β1-, β2-tubulin in purple, GDP in green, GTP in 
yellow, stathmin-like in gray, vinblastine in white; PDB code: 1Z2B104). 
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28 (R1 = CHO) 
29 (R1 = CH3)
30 (R1 = NH2) 
31 (R1 = L-Trp-OC2H5) 
32 (R1 = D-Vla(P)-(OC2H5)2
  
Figure 12. Vinca alkaloid site binding agents. (Continued) 
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Figure 12. Vinca alkaloid site binding agents. 
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4. Arylthioindoles, potent inhibitors of tubulin polymerization 
Paclitaxel and vinca alkaloids are clinically important chemotherapeutic drugs, 
and are widely used for the treatment of a variety of tumors. However, side effects 
and drug resistance reduce their efficacy. Neurological and haematological side 
effects are the principal and often dose-limiting toxicities.111 Drug resistance is 
another factor hampering the clinical applicability of microtubule targeting agents, 
involving the overexpression of drug efflux pumps, and alterations in TB/MTs.112 
These findings highlight the need for novel TB dynamic inhibitors. Furthermore, 
while drugs that act on the vinca and taxane sites have well-established roles in the 
treatment of human cancers, the therapeutic potential of the colchicine site in cancer 
treatment has yet to be realized. Recently, we reported a novel class of TB assembly 
inhibitors, arylthioindoles (ATIs, general structure 35), that bind to the colchicine 
site on β-TB close to interface with α-TB.113-115 ATIs efficiently inhibit tubulin 
polymerization and cancer cell growth, with activities comparable with those of 
colchicine (11) and CSA4 (22). To rationalize the structure-activity relationship 
(SAR) studies we dissected the ATI structure into four regions: (A) the substituent at 
position 2 of the indole, (B) the sulfur atom bridge, (C) the 3-arylthio group, and (D) 
the substituent at position 5 of the indole (Figure 13). In our previous papers we 
reported SAR and molecular modeling studies on ATI derivatives differing in 
substituent groups and/or position at the A, C and D regions.114,115  
However, chemical modification of the sulphur bridge (B region) was not 
exhaustively explored, although five ATIs were transformed into the corresponding 
sulphur dioxides.114 Furthermore the sulphur atom could be converted in vivo to 
corresponding inactive sulfone by human oxidase. In contrast to the weak potency 
displayed by dioxides,114 several CSA4 analogues, characterized by a carbonyl 
functionality as a bridging group between the indole nucleus and the 
trimethoxyphenyl ring, show potent inhibition of tubulin polymerization.116 
4. Arylthioindoles, potent inhibitors of tubulin polymerization 
 
 32
 
 
Figure 13. General structure of ATI’s (35) and reference compounds 11 and 22. 
 
However, in comparing ATIs with the 3-aroylindoles reported by Hsieh and 
coworkers,117 we should note that these two groups of compounds are significantly 
different, since there are major differences in our SAR findings and those of Hsieh’s 
group. Moreover, our molecular modeling studies indicate that in the colchicine site 
of tubulin, ATI derivatives preferentially assume a colchicine-like rather than a 
CSA4-like binding conformation.113-115 These observations prompted the SAR 
investigations at the B bridge. To this end, we synthesized new indole derivatives by 
bioisosteric replacement of the sulphur bridge of the ATI’s with either carbonyl or 
methylene moieties, and other related groups (compounds 36-78, Figure 14, Table 1 
and Table 2). The more active compounds, bearing a sulphur or carbonyl bridge and 
a methoxycarbonyl group at position 2 of indole nucleus, showed an antitumor 
activity comparable to colchicine (11) and CSA4 (22).  
Modeling studies113-115,128 showed that the ester group access to an hydrophobic 
pocket, this could increase the stability of the ligand/receptor complex. It was 
confirmed by biological tests.  
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Figure 14. Structure of compounds 36-78. 
 
However, ester derivative 42 was extensively transformed to in inactive acid in 
metabolic stability experiments assessed in mouse and human liver microsomes 
(Table 16). From previous SAR studies at the (A) region, the elongation of the 2-
methoxy- or 2-ethoxycarbonyl group by means of C3-C5 alkoxy chains or its 
replacement with carboxyamide function lead to a decrease or complete loss of both 
antitubulin and antiproliferative activities, respectively.113,114 Therefore, we planned 
to replace the ethoxycarbonyl group of 42 (A region) with potentially more stable 5-
membered heterocyclic nucleus (pyrrole, furan and thiophene) and aromatic group 
(phenyl, pyridine and naphthyle) as bioisosteres118 (Figure 15 A). Modeling studies 
showed that, with respect to the small/medium linear chain,114 the 5-membered 
heterocycle at the position 2 of the indole nucleus could form new hydrophobic 
interactions with Lys254 and Leu248 into the colchicine site of tubulin (Figure 15 
B). Here, we report the discovery of new potent ATI derivatives designed by 
replacing the ester group of 42 in turn with pyrrole, furane, thiophene, phenyle, 
pyridine and naphthyle (Table 3 and Table 4). 
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Cpd R1 R2 X 
36 H H S 
37 H H C=O 
38 H H CH2 
39 COOMe H S 
40 COOMe H C=O 
41 COOMe H CH2 
42 COOEt H S 
43 COOEt H C=O 
44 COOEt H CH2 
45 H 5-Cl S 
46 H 5-Cl C=O 
47 H 5-Cl CH2 
48 COOMe 5-Cl S 
49 COOMe 5-Cl C=O 
50 COOMe 5-Cl CH2 
51 COOEt 5-Cl S 
52 COOEt 5-Cl C=O 
53 COOEt 5-Cl CH2 
54 COOEt 5-Cl COCH2 
55 COOEt 5-Cl COCO 
56 COOEt 5-Cl CH2CH2 
57 H 5-Br S 
 
Table 1. Structure of compounds 36-57. 
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Cpd R1 R2 X 
58 H 5-Br C=O 
59 H 5-Br CH2 
60 COOMe 5-Br S 
61 COOMe 5-Br C=O 
62 COOMe 5-Br CH2 
63 COOEt 5-Br S 
64 COOEt 5-Br C=O 
65 COOEt 5-Br CH2 
66 H 5-OMe S 
67 H 5-OMe C=O 
68 H 5-OMe CH2 
69 COOMe 5-OMe S 
70 COOMe 5-OMe S=O 
71 COOMe 5-OMe S(=O)2 
72 COOMe 5-OMe C=O 
73 COOMe 5-OMe CHOH 
74 COOMe 5-OMe CH2 
75 COOEt 5-OMe S 
76 COOEt 5-OMe C=O 
77 COOEt 5-OMe CHOH 
78 COOEt 5-OMe CH2 
 
Table 2. Structure of compounds 58-78. 
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Figure 15. A: new ATIs 79-110. B: Binding mode proposed by PLANTS for 42 (yellow stick) and 
90 (white stick) into the colchicine site. H-bond is shown as a light gray dotted line. Residues of the 
binding site and GTP are also reported as lines. 
A 
 
B  
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Cpd R1 X 
79 Pyrrol-2-yl S 
80 Pyrrol-2-yl C=O 
81 Pyrrol-3-yl S 
82 Pyrrol-3-yl C=O 
83 Pyrrol-3-yl CH2 
84 Furan-2-yl S 
85 Furan-2-yl C=O 
86 Furan-2-yl CH2 
87 Furan-3-yl S 
88 Furan-3-yl C=O 
89 Furan-3-yl CH2 
90 Thiophen-2-yl S 
91 Thiophen-2-yl C=O 
92 Thiophen-2-yl CH2 
93 Thiophen-3-yl S 
94 Thiophen-3-yl C=O 
95 Thiophen-3-yl CH2 
 
Table 3. Structure of compounds 79-95. 
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Cpd R1 X 
96 Phenyl S 
97 Phenyl C=O 
98 Phenyl CH2 
99 Pyridin-2-yl S 
100 Pyridin-2-yl C=O 
101 Pyridin-3-yl S 
102 Pyridin-3-yl C=O 
103 Pyridin-4-yl S 
104 Pyridin-4-yl C=O 
105 α-napthyl S 
106 α-napthyl C=O 
107 α-napthyl CH2 
108 β-napthyl S 
109 β-napthyl C=O 
110 β-napthyl CH2 
 
Table 4. Structure of compounds 96-110. 
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5. Chemistry 
Compounds 37, 40, 43, 46, 49, 52, 58, 61, 64, 67, 72, 76, 85, 88, 91, 94, 97, 106, 
109 and 137 were synthesized in a microwave (MW) reactor by treating the 
appropriate indole with 3,4,5-trimethoxybenzoyl chloride in the presence of 
aluminium chloride in 1,2-dichloroethane at 110 °C (150 W) for 2 min. The 
subsequent basic hydrolysis of 137 furnished compound 82 (Scheme 1). Similarly, 
ethyl 5-chloro-3-[2-(3,4,5-trimethoxyphenyl)acetyl]-1H-indole-2-carboxylate 54 
was prepared by MW synthesis using ethyl 5-chloro-1H-indole-2-carboxylate and 2-
(3,4,5-trimethoxyphenyl)acetyl chloride. The latter reagent was obtained by treating 
the appropriate carboxylic acid with oxalyl chloride in the presence of a catalytic 
amount of DMF in anhydrous THF at 0 °C for 10 min (Scheme 2). Reaction of the 
appropriate indole with 3,4,5-trimethoxybenzoyl chloride and methyl magnesium 
bromide in the presence of SnCl4 and ZnCl2 furnished the derivates 80, 100, 102 and 
104 (Scheme 1). Sodium borohydride (10 eq) reduction of 37, 46, 58, 67 and 91 in 
boiling ethanol for 3 h furnished the corresponding benzyl derivatives 38, 47, 59, 68, 
and 92, respectively (Scheme 1). Alternatively, benzyl (41, 44, 50, 53, 62, 65, 74 
and 78) and phenylethyl (56) derivatives were obtained in good yield by treating 
benzoyl (40, 43, 49, 52, 61, 64, 72 and 76) (Scheme 1) or oxalyl (55) (Scheme 2) 
compounds with triethylsilane in trifluoroacetic acid at 25 °C for 12 h. Reduction of 
ketones 72 and 76 with sodium borohydride (1 eq) in refluxing aqueous THF for 2 h 
gave the corresponding alcohols 73 and 77 (Scheme 1). 
MW oxidation of ethyl 3-[2-(3,4,5-trimethoxyphenyl)acetyl]-1H-indole-2-
carboxylate (54) with selenium(IV) oxide in dimethylsulfoxide (DMSO) at 150 °C 
(150 W) for 2 min furnished the corresponding 2-oxo derivative 55 (Scheme 2). 
Compounds 86, 89, 95, 98, 107, 110 and 138 was prepared by treatment of 
respective ketones (85, 88, 94, 97, 106, 109 and 137) with BH3-THF complex in 
acetonitrile and methanol at 70 °C for 1 h. The following basic hydrolysis of 138 
gave compound 83 (Scheme 1). 
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N
H
R2
R1 N
H
R2
R1
OMeMeO
MeO
O
a or b
N
H
R2
R1
X
OMeMeO
MeO
c, d, e, or f
aReagents and reaction conditions: (a) (R1 = H, COOMe, COOEt, (1-phenylsulfonyl)pyrrol-3-yl, furan-2(3)-yl,
thiophen-2(3)-yl, phenyl, -( )-naphthyl; R2 = H, Cl, Br, OMe) 3,4,5-trimethoxybenzoyl chloride, AlCl3,
1,2-dichloroethane, closed vessel, 110 °C, 150 W, Pmax = 250 PSI, 2 min, 30-95%; (b) (R1 = pyrrol-2-yl,
pyridin-3(4)(5)-yl; R2 = H) 3,4,5-trimethoxybenzoyl chloride, 3 M CH3MgBr, 1 M SnCl4, ZnCl2, anhydrous CH2Cl2,
Ar stream, 25 °C, 12 h, 3-70%; (c) (R1 = H, thiophen-2-yl; R2 = H, Cl, Br, OMe) NaBH4 (10 eq), EtOH, reflux, 3 h,
42-68%; (d) (R1 = COOMe, COOEt; R2 = H, Cl, Br, OMe) Et3SiH, CF3COOH, 25 °C, overnight, 46-90%; (e) (R1 =
COOMe, COOEt; R2 = OMe) NaBH4 (1 eq), THF/H2O, reflux, 2 h, 29-53%; (f) (R1 = pyrrol-2-yl, (1-
phenylsulfonyl)pyrrol-3-yl, furan-2(3)-yl, thiophen-3-yl, phenyl, -( )-naphthyl; R2 = H) BH3/THF, CH3CN/MeOH, 50
°C, 1 h, 10-99%; (g) (R1 = (1-phenylsulfonyl)pyrrol-3-yl; R2 = H) 2N NaOH, MeOH, 70 °C, 1 h, 20-98%.
g
N
H
OMeMeO
MeO
O
N
H
OMeMeO
MeO
NH NH
g
37, 40, 43, 46, 49
52, 58, 61, 64, 67
72, 76, 80, 85, 88
91, 94, 97, 100, 102
104, 106, 109, 137
82
38, 41, 44, 47, 50
53, 59, 62, 65, 68
73, 74, 77, 78, 86
89, 92, 95, 98, 107
110, 138
83
137,138 R1 = (1-phenylsulfonyl)pyrrol-3-yl; R2 = H
 
Scheme 1. Synthesis of ketones, alcohols and methylene derivates. 
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OH
O
MeO
OMe
MeO Cl
O
MeO
OMe
MeO
N
H
Cl
OEt
O
OMe
OMe
MeO
O
N
H
Cl
OEt
O
OMe
OMe
MeO
O
O
N
H
Cl
OEt
O
OMe
OMe
MeO
54
55 56
a b
c d
aReagents and reaction conditions: (a) oxalyl chloride, anhydrous DMF cat., anhydrous THF, 0 °C,
10 min; (b) ethyl 5-chloro-1H-indole-2-carboxylate, AlCl3, 1,2-dichloroethane, closed vessel, 110 °C,
150 W, Pmax = 250 PSI, 2 min, 32%; (c) selenium(IV) oxide, DMSO, closed vessel, 150 °C, 150 W,
Pmax = 250 PSI, 2 min, 56%; (d) Et3SiH, CF3COOH, 25 °C, overnight, 40%.  
 
Scheme 2. Synthesis of compounds 54-56. 
 
Compounds 79, 81, 84, 87, 90, 93, 96, 99, 101, 103, 105, 108 and 139 were 
obtained by MW reaction of appropriate indole with bis-(3,4,5-
trimethoxyphenyl)disulfide113 in the presence of sodium hydride in anhydrous DMF 
at 110 °C (150 W) for 2 min (Scheme 3).  
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Scheme 3. Synthesis of sulphur derivates. 
 
The crude carboxylic acid (139) was transformed into the corresponding methyl 
ester 60 with trimethylsilyldiazomethane (TMSDM) in dichloromethane/methanol at 
25 °C for 30 min or into the ethyl ester 63 with thionyl chloride in absolute ethanol 
at 65 °C for 2 h (Scheme 3). Oxidation of methyl 5-methoxy-3-(3,4,5-
trimethoxyphenylthio)-1H-indole-2-carboxylate (69)113 with 1 or 2 eq of 3-
chloroperoxybenzoic acid (MCPBA) in chloroform at 25 °C for 1.5 h gave the 
corresponding sulfoxide (70) or sulfone (71) derivatives, respectively (Scheme 4). 
The required indoles (117-122) was prepared by intramolecular cyclization of the 
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corresponding hydrazone (111-116) in polyphosphoric acid (PPA) as a catalyst, 
according to Fischer’s indole synthesis (Scheme 5). The needed hydrazones (111-
116) was obtained by MW reaction of 4-bromophenylhydrazine and 
phenylhydrazine hydrochloride with appropriate ketone and sodium acetate in 
ethanol at 100 °C (250 W) for 5 min (Scheme 5). MW hydrolysis of ester 117 with 3 
N sodium hydroxide at 110 °C (150 W) for 1 min furnished 5-bromo-1H-indole-2-
carboxylic acid (123), which was transformed into the corresponding methyl ester 
124 by treatment with thionyl chloride in anhydrous methanol at 65 °C for 2 h 
(Scheme 5). Treatment of 1-H-indole with bromine and subsequent reaction of 125 
with pyrrole in the presence of trifluoro acetic acid furnished 126 (Scheme 6a). 
 
 
 
Schema 4. Synthesis of compound 69-71. 
 
The chloride of 2-nitrophenyl acetic acid was treated with 1-(phenylsulfonyl)-1H-
pyrrole in the presence of anhydrous aluminium chloride to give the intermediate 
127, which underwent intramolecular cyclization to 128 with iron powder in glacial 
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acetic acid at 60 °C (Scheme 6b). Reaction of 2-iodo-1H-indole119 (129) with the 
pinacol ester of furan-3-boronic acid in the presence of Pd(II) acetate, potassium 
carbonate in a closed vessel at 110 °C (200 W) for 15 min gave 130 (Scheme 7a).  
2-Acetyl- and 3-acetylthiophene were brominated to 131 and 132 and 
transformed into 133 or 134, respectively, by reaction with aniline in the presence of 
a catalytic amount of DMF in a closed vessel at 100 °C (150 W) for 1 min (Scheme 
7b). Heated at 170 °C of aniline and 135, prepared by reaction of 2-acethyl 
naphthalene and bromine, gave 136 (Scheme 7c). 
 
 
 
Scheme 5. Synthesis of compounds 111-124. 
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N
H
N
H
Br
N
H
H
N
126
a b
125
aReagents and reaction conditions: (a) bromine, anhydrous DMF, 25 °C, 30 min,
light protected; (b) 1-H-pyrrole, CF3COOH, CH2Cl2, 25 °C, 20 min, 18%;
(c) (i) oxalylchloride, catalytic anhydrous DMF, 1,2-dichloroethane, 0 °C,
Ar stream, 30 min (ii) 1-(phenylsulfonyl)-1-H-pyrrole, AlCl3, 0 °C, Ar stream,
15 min, yield 10%; (d) Fe, AcOH, 60 °C, overnight, yield 10%.
NO2
COOH
N
H
N
S
O2
O
N
NO2
O2S
128
c
d
127
a)
b)
 
 
Schema 6. Synthesis of compounds 125-128. 
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N
H
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H
I
N
H
O
130129
S
CH3
O
S
O
Br
N
H
S
131, 132 133, 134
O CH3 O Br
N
H
135 136
a b
c d
e f
a)
b)
c)
aReagent and reaction conditions: (a) (i) n-buthyllithium 2.5 M, CO2, anhydrous THF,
-78 °C, Ar stream, 1 h (ii) ter t-buthyllithium 1.7 M, 1,2-diiodoethane, anhydrous THF,
2 h, -78 °C, Ar stream, 90%; (b) 3-furan boronic acid pinacol ester, Pd(II) acetate,
K2CO3, NMP/H2O, closed vessel, 200 W, 110 °C, Pmax = 250 PSI, 15 min, 95%;
(c) bromine, CH2Cl2, 25 °C, 1 h, 57-80%; (d) (i) aniline, 25 °C, 3 h; (ii) catalytic
anhydrous DMF, closed vessel, 100 °C, 150 W, Pmax = 250 PSI, 1 min, 16-40%; (e)
bromine, CH2Cl2, 25 °C, 1 h, 90%; (f) aniline, N,N-dimethylaniline, 170 °C, 15 min, 30%.
 
 
Scheme 7. Synthesis of compounds 129-136. 
6. Biological activity 
 
 47
6. Biological Activity 
The new bioisosteres at sulphur bridge (36-78) was tested for inhibition of tubulin 
polymerization, growth of MCF-7 human breast carcinoma cells and binding of 
[3H]colchicine to tubulin (more active compounds only), using CSA4 (22) as 
reference compound. Biological data are summarized in Table 5 and 6.  
With few exceptions, tested derivatives showed potent tubulin polymerization 
inhibitory activity. Replacement of the sulphur atom with a carbonyl functionality 
led to compounds endowed with comparable ability to inhibit tubulin assembly 
(compare 36 with 37, 39 with 40, 42 with 43, 45 with 46, 48 with 49, 51 with 52, 57 
with 58, 60 with 61, 63 with 64, 66 with 67, 69 with 70, and 75 with 76), while 
introduction of a methylene group led to inhibitors of tubulin assembly whose 
potency was dependent on the substituent at position 2 of the indole.  
In particular, methylene compounds bearing a methoxy- or ethoxycarbonyl group 
at this position differed little in activities from the corresponding sulphur/carbonyl 
compounds (compare 41 with 39 and 40, 44 with 42 and 43, 50 with 48 and 49, 53 
with 51 and 52, 62 with 60 and 61, 65 with 63 and 64, 74 with 72 and 69, and 78 
with 75 and 76). In contrast, when there was a hydrogen atom at position 2, there 
was a 3-11-fold reduction in inhibitory activity (compare 38 with 36 and 37, 47 with 
45 and 46, 59 with 57 and 58, and 68 with 66 and 67).  
Seven compounds (54-56, 70, 71, 73 and 77) were completely inactive. These 
results clearly indicate forbidden chemical modifications at the B region, namely (i) 
elongation of the bridging group from 1 to 2 atomic units (compounds 54-56); (ii) 
oxidation of the sulphur atom to oxide (70) or dioxide (71), as we also observed in 
our previous paper;114 and (iii) reduction of the carbonyl bridge to an alcohol (73 
and 77). As growth inhibitors of MCF-7 human breast carcinoma cells, the sulphur 
derivatives were superior (compare 36 with 37, 42 with 43, 57 with 58, 66 with 67, 
and 75 with 76) or equivalent (compare 39 with 40, 45 with 46, 48 with 49, 51 with 
52, 60 with 61, 63 with 64, 69 with 72) to the corresponding ketones, while 
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methylene derivatives were usually less effective (compare 41 with 39 and 40, 50 
with 48 and 49, 53 with 51 and 52, 62 with 60 and 61, 65 with 63 and 64, 74 with 69 
and 72, and 78 with 75 and 76). (Generally, only inhibitors of tubulin 
polymerization with IC50 < 5 μM were evaluated for inhibition of MCF-7 cell 
growth). The greatest inhibitory effects on MCF-7 cells were observed with either 
sulphur or carbonyl derivatives bearing a 2-methoxycarbonyl group at position 2 of 
the indole. Compounds bearing either a bromine atom or a methoxy group at 
position 5 and a 2-methoxycarbonyl group at position 2 of the indole were found to 
be potent inhibitors in both the tubulin polymerization and MCF-7 cell growth 
assays, with potencies comparable to those of reference compound 22.  
Worthy of note, among these esters, the methylene derivatives 62 and 74 were 
also highly active in both assays. 
Compounds that inhibited tubulin assembly with IC50's < 5 μM were also 
evaluated for inhibition of the binding of [3H]colchicine to tubulin. Although none 
was as potent as CSA4, significant inhibition was observed with all active agents. 
As usually occurs with a series of antitubulin compounds, there was not a linear 
correlation between colchicine binding inhibition and inhibition of tubulin assembly. 
The most active inhibitor of colchicine binding was compound 69, which was 
almost as active as CSA4, although was about half as active as an inhibitor of 
assembly (IC50's of 2.0 and 1.1 μM, respectively).  
Compounds 60 and 72, both more active than CSA4 as inhibitors of assembly 
(IC50's of 0.99 and 0.67 μM, respectively), were less active than 69 as inhibitors of 
colchicine binding. 
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Cpd R1 R2 X 
Tubulina 
IC50 ± SD 
(μM) 
MCF-7b 
IC50 ± SD 
(nM) 
Inhibition 
Colch. 
bindingc 
(% ± SD) 
36 H H S 2.6 ± 0.2 34 ± 9 68 ± 0.8 
37 H H C=O 3.5 ± 0.07 150 ± 50 26 ± 0.3 
38 H H CH2 28 ± 2 nd nd 
39 COOMe H S 2.9 ± 0.1 25 ± 1 74 ± 2 
40 COOMe H C=O 2.7 ± 0.3 33 ± 10 49 ± 10 
41 COOMe H CH2 4.2 ± 0.02 190 ± 70 33 ± 7 
42 COOEt H S 2.9 ± 0.2 40 ± 2 19 ± 7 
43 COOEt H C=O 2.6 ± 0.3 80 ± 20 51 ± 6 
44 COOEt H CH2 5.4 ± 1 nd nd 
45 H 5-Cl S 2.6 ± 0.2 77 ± 7 51 ± 4 
46 H 5-Cl C=O 2.5 ± 0.5 53 ± 10 44 ± 9 
47 H 5-Cl CH2 24 ± 2 nd nd 
48 COOMe 5-Cl S 2.5 ± 0.3 42 ± 10 73 ± 0.2 
49 COOMe 5-Cl C=O 1.6 ± 0.1 30 ± 6 61 ± 4 
50 COOMe 5-Cl CH2 1.7 ± 0.5 87 ± 30 49 ± 4 
51 COOEt 5-Cl S 2.2 ± 0.2 110 ± 2 53 ± 3 
52 COOEt 5-Cl C=O 1.4 ± 0.2 110 ± 10 49 ± 3 
53 COOEt 5-Cl CH2 2.5 ± 0.5 230 ± 60 39 ± 4 
54 COOEt 5-Cl COCH2 >40 nd nd 
55 COOEt 5-Cl COCO >40 nd nd 
56 COOEt 5-Cl CH2CH2 >40 nd nd 
57 H 5-Br S 1.6 ± 0.3 43 ± 7 65 ± 3 
CSA4 - - - 1.1 ± 0.1 2.5 ± 0.6 99 ± 0.7 
aInhibition of tubulin polymerization. Tubulin was 10 μM during polymerization. bInhibition of 
growth of MCF-7 human breast carcinoma cells. cInhibition of [3H]colchicine binding. Tubulin was 
at 1 μM, both [3H]colchicine and inhibitor were at 5 μM. 
 
Table 5. Inhibition of Tubulin Polymerization, Growth of MCF-7 Human Breast Carcinoma Cells 
and Colchicine Binding by Compounds 36-57 and Reference Compound CSA4 (22). 
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Cpd R1 R2 X 
Tubulina 
IC50 ± SD 
(μM) 
MCF-7b 
IC50 ± SD 
(nM) 
Inhibition 
Colch. 
bindingc 
(% ± SD) 
58 H 5-Br C=O 1.9 ± 0.3 60d 45 ± 5 
59 H 5-Br CH2 13 ± 0.8 nd nd 
60 COOMe 5-Br S 0.99 ± 0.1 33 ± 10 75 ± 3 
61 COOMe 5-Br C=O 1.3 ± 0.08 18 ± 4 67 ± 4 
62 COOMe 5-Br CH2 1.3 ± 0.08 30 ± 9 59 ± 7 
63 COOEt 5-Br S 1.6 ± 0.2 83 ± 20 62 ± 7 
64 COOEt 5-Br C=O 1.6 ± 0.05 67 ± 10 58 ± 2 
65 COOEt 5-Br CH2 1.7 ± 0.2 100d 53 ± 4 
66 H 5-OMe S 4.1 ± 0.6 22 ± 2 61 ± 4 
67 H 5-OMe C=O 3.4 ± 0.4 200d 32 ± 7 
68 H 5-OMe CH2 14 ± 0.5 nd nd 
69 COOMe 5-OMe S 2.0 ± 0.2 13 ± 3 93 ± 0.8 
70 COOMe 5-OMe S=O >40 nd nd 
71 COOMe 5-OMe S(=O)2 >40 nd nd 
72 COOMe 5-OMe C=O 0.67 ± 0.02 17 ± 6 78 ± 6 
73 COOMe 5-OMe CHOH >40 nd nd 
74 COOMe 5-OMe CH2 1.4 ± 0.2 33 ± 10 59 ± 1 
75 COOEt 5-OMe S 2.4 ± 0.2 46 ± 3 71 ± 2 
76 COOEt 5-OMe C=O 2.6 ± 0.04 90 ± 10 49 ± 4 
77 COOEt 5-OMe CHOH >40 nd nd 
78 COOEt 5-OMe CH2 2.8 ± 0.3 93 ± 10 42 ± 4 
CSA4 - - - 1.1 ± 0.1 2.5 ± 0.6 99 ± 0.7 
aInhibition of tubulin polymerization. Tubulin was 10 μM during polymerization. bInhibition of 
growth of MCF-7 human breast carcinoma cells. cInhibition of [3H]colchicine binding. Tubulin was 
at 1 μM, both [3H]colchicine and inhibitor were at 5 μM. dSame value obtained in all experiments. 
 
Table 6. Inhibition of Tubulin Polymerization, Growth of MCF-7 Human Breast Carcinoma Cells 
and Colchicine Binding by Compounds 58-78 and Reference Compound CSA4 (22).  
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The potent esters 57, 60-62, 69, 72 and 74 were evaluated at 0.5 and 1.0 μM for 
cell growth inhibition on human HeLa and HCT116/chr3 cells, derived from a 
cervix uterine carcinoma and a colon carcinoma, respectively.  
All compounds caused about 50% growth inhibition at the lower concentration 
tested (Table 7). Compounds 57, 60-62, 69, 72 and 74 also reduced the viability of 
HEK, M14 and U937 cells in a dose- and time-dependent manner with IC50 values 
ranging from 78 nM (61, M14 cells) to 220 nM (57, HEK cells) (Table 8). 
 
 
 % of Cell Proliferationa,b 
 HeLac HCT116/chr3d 
Cpd 0.5 μM 1 μM 0.5 μM 1 μM 
57 47 ± 0.5 56 ± 1.2 60 ± 0.8 60 ± 3.9 
60 53 ± 0.1 60 ± 0.1 57 ± 0.9 62 ± 1.9 
61 41 ± 1.1 47 ± 0.4 59 ± 0.2 66 ± 3.5 
62 52 ± 0.4 45 ± 1.6 51 ± 4.6 51 ± 1.6 
69 57 ± 1.4 43 ± 0.3 63 ± 1.0 54 ± 1.0 
72 55 ± 0.7 54 ± 0.3 57 ± 3.4 55 ± 1.2 
74 52 ± 0.7 51 ± 0.2 69 ± 6.7 69 ± 0.3 
aData are expressed as % mean values ± SD; control cells are considered as 100% 
(MTT method). bTreatments were performed for 24 h at the indicated 
concentrations. cHeLa cervical cancer cells. dHCT116/chr3 human colon cancer 
cells. 
 
Table 7. Effects of 57, 60-62, 69, 72 and 74 on HeLa and HCT116/chr3 Cell Proliferation. 
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 IC50 ± SD (nM)a 
Cpd HEKb M14c U937d 
57 220 ± 3 194 ± 3 100 ± 3 
60 189 ± 5 155 ± 9 177 ± 10 
61 131 ± 3 78 ± 3 191 ± 7 
62 160 ± 5 120 ± 10 159 ± 10 
69 128 ± 7 111 ± 6 122 ± 6 
72 140 ± 1 100 ± 5 155 ± 10 
74 181 ± 3 137 ± 5 189 ± 5 
aGrowth inhibition of the indicated cell lines (MTT method); 
incubation time was 48 h. bHEK, human embryonic kidney 293 
cells; cM14, human melanoma cells; dU937, human leukemic 
monocyte lymphoma cells. 
 
Table 8. Inhibition of Growth of HEK, M14 and U937 Cells by Compounds 57, 60-62, 69, 72 and 
74. 
 
In contrast, at 300 nM these compounds caused only 20% reduction in murine 
macrophage J744.1 cell growth compared with untreated controls (Figure 16). Thus, 
these compounds were active in six cancer cell lines, but they showed a reduced 
cytototoxic effect on the nonmalignant murine macrophage J744.1 cells. 
This observation with the J744.1 cells raised the possibility that there might be a 
differential effect of esters 57, 60-62, 69, 72 and 74 in malignant and 
nontransformed cells, which in turn would suggest the possibility of a potential 
improvement in the therapeutic index for the ATI’s versus other antitubulin agents. 
Accordingly, we expanded our study of nontransformed cells to an epithelial line 
(PtK2, Potorus tridactylis kidney epithelial cells), two aortic smooth muscle lines 
(human and rat), and an endothelial line (human umbilical vein endothelial cells). 
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Figure 16. Effects of compounds 57, 60-62, 69, 72 and 74 on murine macrophage J744.1 cell 
morphology, as visualized by time-lapse microscopy (magnification 20×). 
 
We also determined the effects of CSA4 and paclitaxel on the growth of these 
four lines (Table 9). In all cases, except for compound 57 with the umbilical vein 
endothelial cells, the ATI’s were more inhibitory than they had been with the J744.1 
cells (that is, all IC50’s were less than 300 nM). The cytotoxicity pattern with each 
agent was different, although compound 69 was the most cytotoxic and compound 
57 was overall the least cytotoxic with these four nontransformed cell lines.  
We devised the MCF-7 SI as a test for the idea that the ATI’s would have 
selective toxicity for a tumor cell line as compared with nonmalignant cells and as 
compared with previously described antitubulin agents. This hope, raised with the 
J744.1 macrophage cells, was not confirmed with the additional cell lines. The 
average SI was 4.8 with CSA4 (22) and 6.1 with paclitaxel (1), although even with 
these two agents specific SI’s differed from each other (the kidney epithelial cells 
were highly sensitive to CSA4, while both muscle lines were relatively resistant; 
57 60 61 62 69 72 74 
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with paclitaxel, the human muscle cells were most sensitive, the rat muscle cells 
most resistant). The average SI with the esters ranged from 4.3 with compound 74 to 
7.3 with compound 61. We conclude that there is no significant difference between 
compounds 57, 60-62, 69, 72 and 74 as compared with CSA4 and paclitaxel. 
The effect of drug treatment on cell morphology was examined by time-lapse 
microscopy (TLM) using a Leica CTR6500 microscope. Cells were kept at 37 °C 
under a 5% carbon dioxide atmosphere for 48 h. The cytotoxic effects of compounds 
57, 60-62, 69, 72 and 74 on HEK and M14 cell growth increased in a concentration- 
and time-dependent manner. Figure 17 shows the effects of 57, 72 and 74 after a 48 
h treatment. Control HEK and M14 cell cultures displayed elongated bipolar or 
polygonal morphology, while a significant effect on cell morphology and 12-30% 
growth inhibition was already observed as early as 12 h after compound addition. 
The treatment for 48 h with 57, 72 or 74 induced significant morphologic changes 
in both cell lines, which became rounded and developed large vacuoles. Moreover, 
cells of both lines were less elongated than the untreated controls, and some cells 
that became rounded also had a tendency to detach from the substrate. Similar 
changes were observed after treatment with 60-62 and 69. 
Saccharomyces cerevisiae budding yeast has been used to enhance understanding 
of fundamental cellular and molecular processes occurring in mammalian cells, 
including DNA replication, DNA recombination, cell division, protein turnover, 
vesicular trafficking and mechanisms involved in longevity of cell life and cell death. 
Approximately 31% of yeast genes have a mammalian homologue, and an additional 
30% of yeast genes show domain similarity.120 
Potentially, yeast can be a powerful model for the development of cell death-
directed drugs. For example, paclitaxel, arsenic, bleomycin and valproate induce 
apoptotic phenotypes in yeast.121 Yeast have increased our understanding of the 
pathogenic role of human proteins in neurodegenerative diseases.122 
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 IC50 ± SD (nM)a 
Cpd MCF-7 
HAOSMCb 
(MCF-7 SI)f 
PtK2c 
(MCF-7 SI) 
A10d 
(MCF-7 SI) 
HUVECe 
(MCF-7 SI) 
57 
43 ± 7 
- 
300 ± 200 
(7.0) 
230 ± 100 
(5.3) 
210 ± 100 
(4.9) 
400 ± 100 
(9.3) 
60 
33 ± 10 
- 
100 ± 30 
(3.0) 
280 ± 30 
(8.5) 
230 ± 100  
(7.0) 
140 ± 20 
(4.2) 
61 
18 ± 4 
- 
55 ± 40 
(3.1) 
110 ± 60 
(6.1) 
280 ± 40 
(16) 
150 ± 0g 
(8.3) 
62 
30 ± 9 
- 
35 ± 7 
(1.2) 
270 ± 100 
(9.0) 
230 ± 100 
(7.7) 
140 ± 20 
(4.7) 
69 
13 ± 3 
- 
15 ± 7 4 
(1.2) 
78 ± 50 
(6.0) 
70 ± 70 
(5.4) 
38 ± 30 
(2.9) 
72 
17 ± 6 
- 
35 ± 7 
(2.1) 
190 ± 20 
(11) 
95 ± 80 
(5.6) 
110 ± 60 
(6.5) 
74 
33 ± 10 
- 
70 ± 10 
(2.1) 
190 ± 200 
(5.8) 
130 ± 100 
(3.9) 
170 ± 50 
(5.2) 
CSA4 
2.5 ± 0.6 
- 
18 ± 4 
(7.2) 
1.0 ± 1 
(0.4) 
23 ± 10 
(9.2) 
5.0 ± 5 
(2.0) 
Ptxh 
3.0 ± 0.5 
- 
6.0 ± 6 
(2.0) 
21 ± 8 
(7.0) 
38 ± 10 
(13) 
7.0 ± 4  
(2.3) 
aGrowth inhibition of the indicated cell lines. bHAOSMC: human aortic smooth muscle cells (ATCC #CLR-
1999); cPtK2: potorous tridactylis kidney epithelial cells (ATCC #CLL-56); dA10, rat embryonic aortic 
smooth muscle cells (ATCC #CRL-1476); eHUVEC: human umbilical vein endothelial cells (ATCC #CRL-
2873). fMCF-7 SI: selectivity index (SI) for each agent in each cell line versus the MCF-7 cells (IC50 in 
specific cell line divided by IC50 in MCF-7 cells; the higher the SI, the more resistant the nontransformed 
cell line relative to the MCF-7 cells). gSame value obtained in both experiments. hPtx: paclitaxel. 
 
Table 9. Inhibition of Growth and MCF-7 Selectivity Index of HAOSMC, PtK2, A10 and HUVEC 
Cells by Compounds 57, 60-62, 69, 72 and 74, and Reference Compounds CSA4 (22) and Ptx (1). 
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Figure 17. Effects of compounds 57, 72 and 74 on HEK (top) and M14 (bottom) cell morphology 
and growth as seen by TLM (magnification 10x). 
57
72 
74 
74 
72 
57 
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Finally, Cassidy-Stone and coworkers123 identified MDIVI-1 (mitochondrial 
division inhibitor-1) by yeast screens of chemical libraries. A protocol was set up to 
evaluate the toxicity of compounds 57 and 60-62 on BY4741, a standard laboratory 
wild type strain of S. cerevisiae.  
  
untreated
DMSO
24
28
29
 
 
 
 
Figure 18. Effect of compounds 57, and 60-62 on BY4741 wild type strain. Growth was recorded 
after 3 days at 28 °C; final compound concentration was 20 μM. aSCD, Serial Cell Dilution. 
 
As shown in Figure 18, 57 strongly reduced the viability of the BY4741 strain 
cells, which were cell growth limited at the first dilution (the second showed limited 
cell growth). Compound 62 also showed significant BY4741 inhibition (cell growth 
was limited to the third dilution). Despite the small test set used in this experiment, 
the ester functionality of 60-62 clearly caused a drop in activity, as compared with 
the most potent compound 57 lacking the ester group.  
57 
61 
62 
27
0 1 2 3pSCDa
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The new bioisosteres 79-110 were valued as inhibitors of both tubulin 
polymerization and growth of MCF-7 human breast carcinoma cells, and for the 
most active compounds were determined  the displacement of the [3H]colchicines 
from the TB-binding site. Combretastatine A4 (22), colchicine (11) and 39 were 
used as reference compounds (Table 10 and Table 11). The new ATIs (79-95), 
bearing a 5-membered heterocyclic nucleus at position 2 of indole, inhibited tubulin 
polymerization with IC50’s ranging from 0.74 to 6.8 µM, and in particular 
compounds 90 and 93, characterized by the presence of a thiophene ring and sulphur 
bridge at positions 2 and 3 of the indole ring respectively, were more potent than 
reference compounds (90: IC50 = 0.74 μM, 93: IC50 = 0.91 μM, 22: IC50 = 1.1 μM, 
11: IC50 = 3.2 μM, 39: IC50 = 2.9 μM,  Table 10). Replacement of the sulphur atom 
with a carbonyl functionality led to compounds with comparable ability to inhibit 
tubulin assembly (compare 80 with 79, 82 with 81, 84 with 83, 86 with 85, 89 with 
88, 91 with 90 and 94 with 93), while the introduction of a methylene group led to a 
2-6 fold reduction in inhibitory activity (compounds 83, 86, 89, 92, and 95). 
In the inhibition of the growth of human MCF-7 non-metastatic breast cancer 
epithelial cells assay, the sulphur and carbonyl derivates showed IC50’s ranging from 
10 to 60 nM, and the most active compounds were 79 (IC50 = 18 nM), 80 (IC50 = 10 
nM) and 81 (IC50 = 20 nM). Compounds with a methylene bridge were usually less 
effective.  
All sulphur and ketones derivatives were strong inhibitors of the binding of 
[3H]colchicine (61-93% inhibition, although not quite as potent as CSA4). In this 
assay, the strongest inhibition was observed with compounds 79 (92%) and 87 
(93%). In contrast, the methylene derivatives showed an inhibition less of 56%. 
Compounds 96-104 bearing a 6-membered aromatic groups at position 2 of the 
indole ring were less potent as inhibitors of MCF-7 cell grown than the 
corresponding 5-member heterocyclic; only derivates 101 and 103 were potent as 
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the reference compounds (Table 11), and showed 88 and 91% inhibition of the 
binding of [3H]colchicine to tubulin, respectively. 
 Finally, the introduction of the steric hindered α- or β-naphthalene moiety led to 
inactive compounds. 
The antiproliferative activity of compounds 81 and 90-92 was evaluated in four 
additional cancer cell lines in comparison with doxorubicin (DOX), a common 
DNA-targeting drug often employed in association with anti-mitotic agents (Table 
12). Compounds 90 and 91 were generally one order of magnitude more potent as 
growth inhibitors of HeLa (cervix), PC3 (prostate), HT-29 (colon), A549 (non small 
cell lung) and 231-MDA (metastatic breast) carcinoma-derived cell lines as 
compared with DOX. Compound 81 was highly effective in the HT-29 and A549 
cell lines, and less active in the HeLa and PC3 cell lines. Compound 92 was 
generally comparable with DOX. These data underscore the effectiveness of ATIs 
81 and 90-92 in transformed cell types. Such results also highlighted a differential 
sensitivity to MT-targeting drugs displayed by cell lines with different genetic 
background, consistent with results obtained with other drugs that target the mitotic 
apparatus.124,125 
For compound 81 and 91 was analyzed growth inhibition in an ovarian cancer 
model with high drug sensitivity (A2780wt), its cisplatin-resistant counterpart 
(A2780-CIS) and a cell line derived from a cisplatin-resistant patient (OVCAR-3) 
(Table 13). For the acquired cisplatin-resistance (RI-1) model, compounds 81 and 91 
yielded even lower IC50 than in the parental line, in contrast to the almost 20-fold 
resistance to cisplatin. On the other hand, such an increase was not detectable in the 
endogenous resistance model as the resistance values (RI-2) for the two ATIs were 
essentially identical to that obtained with cisplatin in OVCAR-3. Taken together, 
these results indicate the ATIs can target a broad range of cancer tissues, with a 
selective activity against acquired cisplatin resistance. 
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Cpd R1 X 
Tubulina 
IC50 SD 
(μM) 
MCF-7b 
IC50 SD 
(nM) 
Inhibition 
Colch. 
Bindingc 
(% ± SD) 
79 Pyrrol-2-yl S 1.1 ± 0.05 18 ± 6 92 ± 0.6 
80 Pyrrol-2-yl C=O 1.4 ± 0.2 10 ± 0 79 ± 3 
81 Pyrrol-3-yl S 1.2 ± 0.2 20 ± 0 85 ± 1 
82 Pyrrol-3-yl C=O 1.8 ± 0.2 35 ± 7 71 ± 0.7 
83 Pyrrol-3-yl CH2 3.0 ± 0.2 600 ± 0 56 ± 7 
84 Furan-2-yl S 1.0 ± 0.1 45 ± 4 - 
85 Furan-2-yl C=O 1.9 ± 0.2 55 ± 7 78 ± 0.3 
86 Furan-2-yl CH2 6.8 ± 1 nd nd 
87 Furan-3-yl S 1.0 ± 0.1 33 ± 5 93 ± 4 
88 Furan-3-yl C=O 1.1 ± 0.007 40 ± 20 77 ± 0.8 
89 Furan-3-yl CH2 6.5 ± 0.08 nd nd 
90 Thiophen-2-yl S 0.74 ± 0.05 39 ± 10 - 
91 Thiophen-2-yl C=O 1.0 ± 0.1 36 ± 6 75 ± 3 
92 Thiophen-2-yl CH2 1.9 ± 0.2 200 48 ± 5 
93 Thiophen-3-yl S 0.91 ± 0.2 60 ± 20 - 
94 Thiophen-3-yl C=O 2.1 ± 0.08 40 ± 0 61 ± 3 
95 Thiophen-3-yl CH2 2.7 ± 0.08 340 ± 200 52 ± 4 
39 COOMe S 2.9 ± 0.1 25 ± 1 74 ± 2 
Colch   3.2 ± 0.4 13 ± 3 - 
CSA4   1.1 ± 0.1 2.5 ± 0.6 99 ± 0.7 
aInhibition of tubulin polymerization. Tubulin was 10 μM during polymerization. 
bInhibition of growth of MCF-7 human breast carcinoma cells. cInhibition of 
[3H]colchicine binding. Tubulin was at 1 μM, both [3H]colchicine and inhibitor were at 5 
μM. 
 
Table 10. Inhibition of Tubulin Polymerization, Growth of MCF-7 Human Breast Carcinoma Cells 
and Colchicine Binding by Compounds 79-95 and Reference Compounds 39, 11, and 22. 
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Cpd R1 X 
Tubulina 
IC50 SD 
(μM) 
MCF-7b 
IC50 SD 
(nM) 
Inhibition 
Colch. 
Bindingc 
(% ± SD) 
96 Phenyl S 3.3 ± 0.1 52 ± 7 nd 
97 Phenyl C=O 5.7 ± 0.06 87 ± 20 nd 
98 Phenyl CH2 3.7 ± 0.3 170 ± 60 50 ± 3 
99 Pyridin-2-yl S 1.5 ± 0.2 180 ± 80 48 ± 6 
100 Pyridin-2-yl C=O > 20 330 ± 100 nd 
101 Pyridin-3-yl S 1.3 ± 0.07 12 ± 7 88 ± 0.1 
102 Pyridin-3-yl C=O 6.3 ± 0.7 200 ± 100 nd 
103 Pyridin-4-yl S 0.95 ±  0.1 16 ± 10 91 ± 2 
104 Pyridin-4-yl C=O 6.0 ± 0.6 170 ± 60 nd 
105 α-naphthyl S >40 nd nd 
106 α-naphthyl C=O >40 nd nd 
107 α-naphthyl CH2 >40 nd nd 
108 β-naphthyl S 1.0 ± 0.06 530 ± 50 51 ± 6 
109 β-naphthyl C=O >40 nd nd 
110 β-naphthyl CH2 >40 nd nd 
39 COOMe S 2.9 ± 0.1 25 ± 1 74 ± 2 
Colch   3.2 ± 0.4 13 ± 3 - 
CSA4   1.1 ± 0.1 2.5 ± 0.6 99 ± 0.7 
aInhibition of tubulin polymerization. Tubulin was 10 μM during polymerization. 
bInhibition of growth of MCF-7 human breast carcinoma cells. cInhibition of 
[3H]colchicine binding. Tubulin was at 1 μM, both [3H]colchicine and inhibitor were at 5 
μM. 
 
 
Table 11. Inhibition of Tubulin Polymerization, Growth of MCF-7 Human Breast Carcinoma Cells 
and Colchicine Binding by Compounds 96-110 and Reference Compounds 39, 11 and 22. 
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 IC50 ± SD (μM)a 
Cpd HeLa PC3 HT-29 A549 
81 0.4 ± 0.02 0.5 ± 0.1 0.1 ± 0.03 0.08 ± 0.02 
90 0.09 ± 0.002 0.2 ± 0.05 0.15 ± 0.03 0.09 ± 0.02 
91 0.07 ± 0.004 0.1 ± 0.08 0.08 ± 0.01 0.08 ± 0.01 
92 1 ± 0.03 2 ± 0.1 1 ± 0.05 2 ± 0.08 
DOXb 1.5 ± 0.03 1.7 ± 0.02 1.0 ± 0.04 1.0 ± 0.08 
aGrowth inhibition of the indicated cell lines (MTT method); incubation time was 48 h. 
bDoxorubicin as reference compound. 
 
Table 12. Inhibition of Growth of HeLa, PC3, HT29, and A549 Cell Lines by Compounds 81 and 90-
92. 
 
Compounds 81, 90 and 91 were compared with vinorelbine (33), vinblastine (29), 
PTX (1) and CSA4 (22) in the OVCAR-8 and NCI/ADR-RES cell lines (Table 14). 
Derived from OVCAR-8, NCI/ADR-RES is an adriamicyn-resistant cell line that 
overexpresses P-glycoprotein (Pgp), resulting in the type 1 multidrug-resistance 
phenotype. Compounds 81, 90 and 91 were uniformly more active in the NCI/ADR-
RES line than in the parental OVCAR-8 line. Both compounds showed a less 
differential activity, however, than did PTX (1), and CSA4 (22) was the least 
selective of the compounds evaluated. In contrast, VRB and VBL showed the typical 
multidrug resistance differential, as did PTX. CSA4 yielded the same IC50 in both 
cell lines and clearly was not a Pgp substrate. Most importantly, as NCI/ADR-RES 
cell growth inhibitors, ATIs 81, 90 and 91 were all superior to VRB, VBL and PTX. 
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 IC50 ± SD (nM) 
Cpd A2780wt A2780-CIS OVCAR-3 RI-1a RI-2b 
81 21.5 ± 1.2  6.3 ± 1.8 81 ± 21 0.29 3.8 
91 30.5 ± 0.7  29.3 ± 3.2 117 ± 18 0.96 3.8 
Cisplatin 485 ± 60 8980 ± 565 1816 ± 254 18.5 3.7 
aRI-1 (Resistant Index-1) was calculated by dividing the IC50 obtained in A2780-CIS by 
the IC50 obtained in A2780wt. bRI-2 (Resistant Index-2) was calculated by dividing the 
IC50 obtained in OVCAR-3 by the IC50 obtained in A2780wt. A value >1 or <1 means 
either increased cisplatin-resistance or sensitivity, respectively. 
 
Table 13. Growth Inhibition in A2780wt Cells, its Cisplatin Resistant Counterpart A2780-CIS and 
OVCAR-3 by Compounds 81 and 91. 
 
These compounds were from 200- (81 and 90) to 333-fold (91) more potent than 
VRB, from 13- (81 and 90) to 8-fold (91) more potent than VBL, and from 100- (81 
and 90) to 60-fold (91) more potent than PTX. 
A recurrent problem with MT-targeting drugs is their widespread toxicity on 
normal cells when used in human patients.7,126,127 We therefore used non-
transformed cells to evaluate potential differences between compounds 81 and 92, as 
representatives of one of the more potent ATIs and the least potent in the current 
series as MCF-7 grown inhibitor (Table 15). Both compounds 81 and 92 had 
somewhat greater antiproliferative effects in MCF-7 breast cancer cells as compared 
with several non-transformed cell lines, with the difference being greater for 81 than 
92. 
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 IC50 ± SDa (nM) 
Cpd OVCAR-8b NCI/ADR-RESc 
81 70 ± 30 25 ± 7 
90 45 ± 20 25 ± 7 
91 20 ± 10 15 ± 7 
VRBd 300 ± 0 5000 ± 1000 
VBLe 15 ± 7 200 ± 0 
PTX 2 ± 0.7 1500 ± 700 
CSA4 1.3 ± 0.6 1.3 ± 0.6 
aCells were grown in RPMI 1640 medium with 5% FBS, 5% 
CO2 atmosphere at 37 °C, for 96 h. bOVCAR-8: ovarian tumor 
cell line 8. cNCI/ADR-RES: driamicyn resistant cell line derived 
from OVCAR-8. dVinorelbine, tubulin inhibition = 3.1 ± 0.2 µM. 
eVinblastine, tubulin inhibition = 1.1 ± 0.2 µM. 
 
Table 14. Growth Inhibition of OVCAR-8 and NCI/ADR-RES Cells Lines by Compounds 81, 90, 91 
and Reference Compounds VRB (33), VBL (29), PTX (1) and Colch (22). 
 
To further characterize the cell growth inhibitory properties of the new ATIs, 
compounds 81 and 90-92 were analyzed for their effects on the cell cycle in parallel 
with VBL (29) and CSA4 (22) (Figure 19). 24 h after plating, HeLa cells were 
exposed to each compound for 24 h, and the cell cycle profile was subsequently 
analyzed by flow cytometry. We found that 81, 90 and 91 at 100 nM consistently 
blocked cell cycle progression and induced 70-90% of the cells to accumulate in the 
G2/M phases (Figure 19), similar to VBL (29) and CSA4 (22) (80-90% G2/M arrest).  
The cell cycle effects of ATIs 90 and 91 were further examined in the A549 and 
HT29 cell lines. 
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   IC50 ± SD (nM)  
Cpd MCF-7 HAOSMCa A10b PtK2c HUVECd 
81 20 ± 0  33 ± 10 40 ± 30 60 ± 0 30 ± 0 
92 200 ± 0 250 ± 90 150 ± 90 300 ± 0 180 ± 40 
CSA4 13 ± 3 5 ± 3 1 ± 1 3 ± 1 1 ± 1 
PTXe 3 ± 0.5 6 ± 6 38 ± 10 21 ± 8 7 ± 4 
aHAOSMC: human aortic smooth muscle cells (ATCC #CLR-1999); bA10, rat embryonic 
aortic smooth muscle cells (ATCC #CRL-1476); cPtK2: potorous tridactylis kidney 
epithelial cells (ATCC #CLL-56); dHUVEC: human umbilical vein endothelial cells 
(ATCC #CRL-2873). eData from Lit.128 
 
Table 15. Growth Inhibition of MCF-7, HOSMAC, A10, PtK2 and HUVEC Cells Lines by 
Compounds 81, 92, CSA4 (22) and PTX (1). 
 
Both 90 and 91 induced a gradual accumulation of cells in the G2/M phase of the 
cell cycle in a dose-dependent manner, could be detected as early as 7 h after 
treatment (Figure 20 and Figure 21 A). In these cells we evaluated both the cell 
cycle profile and the accumulation of cyclin B1 (Figure 21 B) following treatment 
with the compounds. Both flow cytometry and the Western blot assay for cyclin B1 
provide information about the entire cell population. Yet, these experiments do not 
provide definitive proof that the cells are actually arrested in mitosis, as would be 
expected following treatment with a microtubule inhibitor.  
Cells arrested in mitosis can either induce cell death or re-enter interphase and 
further replicate their DNA, becoming polyploid and increasing the degree of 
genetic instability of the cell population. To distinguish between these cell fates after 
ATI treatment, we processed cell cultures for immunofluorescence to α-tubulin and 
stained chromosomes with the DNA dye 4',6-diamidino-2-phenylindole (DAPI). 
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Figure 19. The effect of ATIs on cell cycle progression in HeLa cell cultures. A. Bright-field panels from HeLa cell cultures 
exposed to the DMSO solvent only or exposed to the indicated compounds (VBL and 22 at 20 nM and the other compounds at 
100 nM). Cells arrested in mitosis show a typical rounded, highly refractive morphology resulting in a highly refractive 
phenotype (10x objective). B. Typical flow cytometry profiles of cell cultures exposed to the indicated compounds at the same 
concentrations as in A. C. Bars represent the % of cells with G2/M genomic content after treatment with each compound at the 
indicated concentration (mean values ± SD were calculated from 2 to 6 independent experiments).  
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22 
42 
81 
90 
91 
92 
A B             C  
% [G2 + M] cells 
6. Biological activity 
 
 67
 
 
Figure 20. Dose-dependent cell cycle effects of 91 in A549 cell cultures. Typical cell cycle profiles 
after flow cytometric analysis of A549 cell populations treated with DMSO only (A) or with 91 (B) 
(100 nM, 7 h). 
A 
B 
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Figure 21. A. The histograms represent the % of cells with G1, S and G2/M DNA content, based on 
flow cytometric analyses in A549 cells exposed to increasing µM concentrations of ATIs 90 and 91 
(7 h). B. Cyclin B1 accumulation in A549 and HT29 cell lines exposed to the indicated µM 
concentrations of 91 (7 h). 
B 
A 
90 91
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Treated and control cells were then scored for their mitotic index (MI) calculated 
as mitotic cells/(mitotic + interphase cells) ratio. In control cultures, about 10% of 
cells were in the various stages of mitosis with well-formed spindles interacting with 
condensed chromosomes (Figure 22 A). In cultures exposed to ATI 81, 90 or 91, 
over 60% of the cells were arrested in prometaphase with condensed chromosomes 
but no spindle (Figure 22 B). Thus, the accumulation of G2/M cells detected by flow 
cytometry does indeed reflect a true mitotic arrest. The MI in cell populations 
treated with 81, 90 and 91 was significantly higher compared to treatment with the 
weak tubulin inhibitor 92. The MIs observed with 81 and 91 were in the same range 
as CSA4 (22) and VBL (29), although a higher concentration of the ATIs was 
required (Figure 22 C). The data at this point indicate that most ATIs that effectively 
inhibited tubulin polymerization in vitro did indeed arrest mitotic progression in 
cultured cells, thereby causing decreased cell proliferation in human transformed 
cell lines. To investigate more closely the link between mitotic arrest and reduced 
cell growth, we analyzed HeLa cell populations exposed to 81 and 90-92 for 
induction of cell death under the same conditions used in the mitotic arrest 
experiments. Control cultures were compared with cultures treated with ATIs 81, 90 
and 91 for their reactivity to annexin V, which binds to phosphatidylserine residues 
that are translocated from the inner to the outer cell membrane in early apoptosis.  
Annexin V-reactive cells were quantitated by flow cytometry (Figure 23 A). The 
results showed that 81, 90 and 91 induced apoptosis as efficiently as CSA4 (22) and 
VBL (29) at the concentrations examined (Figure 23 B). To extend these results, we 
analyzed the induction of caspase-3 expression at the single cell level.  
Caspase-3 regulates the induction of apoptosis in mitotic cells, and it is required 
for the apoptotic response to MT-targeting drugs.129 
 
6. Biological activity 
 
 70
 
 
 
 
 
 
 
 
 
Figure 22. Induction of mitotic arrest by ATIs. A. HeLa control cultures exposed to DMSO solvent (0.1%, 24 h); MTs are 
visualized by α-tubulin staining (green) and chromosomes by DNA staining (blue); most cells are in interphase; cells in various 
stages of mitotic progression (PM, prometaphase; M; metaphase) are indicated. B. A typical field from a HeLa culture exposed 
to ATI 91 (100 nM, 24 h); note that most cells are arrested in early mitotic stages with condensed chromosomes and a failure 
to assemble proper MTs; disorganized tubulin foci are seen throughout the mitotic cells. C. MIs in HeLa cell cultures that were 
treated with DMSO solvent, with known anti-MT compounds, or with ATIs 81 and 90-92 (mean values ± SD were calculated 
from 2 to 4 independent experiments). 
81 90 91 92 
91 
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Immunofluorescence showed that 81, 90 and 91, but not 92, induced caspase-3 
activity in a significant fraction of cells (an apoptotic cell treated with 91 is shown in 
Figure 23 C), further demonstrating the strong link between the ability of ATIs to 
arrest mitotic progression and to induce apoptosis.  
The metabolic stability of 42, 81, 90 and 91 was evaluated in mouse and human 
liver microsomes to estimate stability to phase I oxidative metabolism (Table 16). 
Compounds 81 and 91, respectively, showed a medium and low metabolic 
stability in both human and mouse liver microsomes, while 90 exhibited medium 
stability in the human microsomes and low stability in the mouse microsomes. In 
contrast, the metabolic stability of 42 was dramatically low.  
The metabolic stability of 81, 90 and 91 seemed to be dependent on the nature of 
the 2-heterocyclic nucleus rather than the structure of the bridging group. Such an 
effect may be explained by steric hindrance exerted by the two aromatic moieties 
attached to the bridging group. 
The aqueous solubility of 81 increased 4 times over that of compound 42, as a 
result of the introduction of the pyrrole nucleus for the ester function. The aqueous 
solubility of 81 at pH 7.4 was 20 μM, while under the same conditions the solubility 
of 42 was 5 μM. Most importantly, such an improvement of the solubility of 81 
impacted with 2.4- and 2.0-times increases, respectively, of tubulin polymerization 
and MCF-7 growth inhibitory potencies.  
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Figure 23. Induction of apoptosis by ATIs. A. Typical flow cytometry studies of HeLa cell populations incubated with annexin 
V after exposure to DMSO only (control) or to 91 (100 nM). B. The histograms represent the % apoptotic cells, as determined 
by annexin V-reactivity, after exposure to the indicated compounds for 24 h (means ± SD were calculated from 2 to 3 
experiments). C. Single-cell level immunofluorescence analysis revealed by the induction of active caspase-3 (recognized by a 
specific antibody): the panels depict typical fields from HeLa cultures exposed to only DMSO (note the two cells progressing 
through mitosis) or to 91 (a mitotic cell expressing active caspase-3 is indicate by the arrow among a group of cells arrested in 
mitosis). 
100 nM 91 
DMSO      VBL     CSA4      90         91          81
                10 nM     20 nM     100 nM   100 nM   100 nM  
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 % remaining at 30 min.a 
Cpd Human Liver microsomes Mouse Liver microsomes 
81 34.8 ± 1.4  23.1 ± 0.6 
90 22.0 ± 1.0 2.2 ± 0.3 
91 4.6 ± 0.2  0.60 ± 0.01  
42 0.37 ± 0.01  0.5 ± 0.03  
7-Ethoxycoumarinb 6.6 ± 0.2 0.07 ± 0.02 
Propranololb 54.1 ± 0.4 20.6 ± 0.5 
aMetabolic stability: >95, high; 50-95, good; 10-50, medium; <10, low. bResults are 
expressed as mean ± SD,  n=2. bThe standard compounds 7-ethoxycoumarin and 
propranolol showed metabolic stability in agreement with the literature and internal 
validation data.130 
 
Table 16. Metabolic stability results of 42, 81, 90 and 91 in human and mouse liver microsomes.a 
 
Finally, for its interesting in vitro properties, the intravenous pharmacokinetic and 
oral bioavailability of 81 was investigated in the mouse. Pharmacokinetic studies 
were carried out in male CD–1 mice. The compound was either administered in 
single intravenous (iv) injections of 5 mg/kg or oral (os) dose of 15 mg/kg, 
respectively. The main pharmacokinetic parameters obtained are reported in Table 
17. Compound 81 showed a systemic plasma clearance slightly lower than the 
hepatic blood flow of 86 mL/min/kg in mice, an estimated elimination half life of 40 
minutes and a calculated steady state volume of distribution suggestive of good 
tissue distribution. Moreover, the compound was quickly absorbed after oral 
administration and showed a very high oral bioavailability. 
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Parameter  
Cmaxaiv (ng/mL) 35.67 
AUC0-∞biv (ng.min/mL) 174346 
t1/2c (min) 40 
Cld (mL/min/kg) 28.6 
Vsse (L/kg) 1.59 
Cmaxaos (ng/mL) 1340 
tmaxfos (min) 120 
AUC0-∞bos (ng.min/mL) 583315 
Fg (%) 110 
aMaximum concentration; barea under the curve calculated 
up 0-∞ timepoint; chalf-time; dclearance; emean distribution 
volume; fmax-time; goral bioavailability. 
 
Table 17. Pharmacokinetic Properties of 81 in Mice. 
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7. Molecular modeling 
The binding mode of ATIs was extensively studied by means of docking 
experiment. Based on our previous modeling results,113-115 we performed a series of 
docking simulations on a virtual library of structures with different bridges (B) in 
order to identify the most promising compounds before their actual synthesis. The 
aim of the simulations was to find a bridge group able to retain or improve the 
biological activity with an increased metabolic stability in comparison with sulphur 
atom which could be metabolized in vivo. The results obtained for the new series 
showed that the sulphur atom (B) replacement with a methylene or carbonyl moiety 
led to virtually identical docking poses previously reported for ATIs (Figure 24). 
 
 
 
Figure 24. Docking poses for reference compounds 69 (white stick). H-bonds are reported as yellow 
dotted lines. Residues of the binding site and GTP are also reported as lines. 
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In particular, the trimethoxyphenyl moiety was situated in close proximity to 
Cys241, and the indole NH formed a hydrogen bond with Thr179 (Figure 25). These 
results let to suppose as these bridge modifications would lead to strong biological 
activity, it was confirmed by the experimental results. Conversely, results for 
compounds with a two-carbon bridge were different. Such structures adopted a 
binding conformation in the colchicine site far from the one observed for previously 
reported ATIs: the trimethoxyphenyl ring was far away from Cys241, that could be 
related with poor binding and low biological activity. To test the model we 
synthesized only three 2-carbon bridge analogues (54-56) for which the 
experimental data confirmed the predictions of the docking studies. 
  
 
 
Figure 25. Docking poses for compounds 69 (white stick), 72 (yellow stick) and 74 (light blue stick). 
Residues of the binding site and GTP are also reported as lines. 
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The metabolic instability showed by the sulphur bridge atom was overcame by an 
in silico approach. Thanks to the good results obtained we decided to repeat the 
same approach to solve the metabolic instability also of the ester moieties that might 
be hydrolyzed to the corresponding acid in vivo. With this goal in mind we built a 
small virtual library of structures in which the ester groups of ATI 69 (Figure 24) 
was replaced by different 5-membered heterocycles (pyrrole, furan or thiophene). 
Docking simulations with FlexX131 into the colchicine site on tubulin showed a 
consistent binding pose for the new 5-membered ring analogues (Compound 79 and 
90) (Figure 26). 
  
 
 
Figure 26. Binding mode proposed by PLANTS for 69 (white stick), 79 (light pink stick) and 90 
(light blue stick) into the colchicine site. Residues of the binding site and GTP are also reported as 
lines. 
Leu248 
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In particular, the 5-membered heterocycle introduced into the ATIs scaffold 
formed new hydrophobic interaction with the Lys254 and Leu248 side chains, while 
occupying the same pocket of the ester function. As a validation of these findings, 
we repeated the docking simulations with PLANTS132 and GLIDE133. The obtained 
binding pose were consistent with the binding conformations obtained by FlexX. In 
particular, the trimethoxyphenyl group lay in proximity to the Cys241, Met259 and 
Leu255 residues, and the indole NH established a key H-bond with Thr179 
(conventional residue numbering was used).115 
For one of the most active compounds (90) we carried out a molecular dynamics 
simulation of the tubulin/90 complex. The trajectory analysis showed that, during 
the 5 ns of simulation, the binding pose of 90 remained relatively stable. The H-
bond between the Thr179 and the indole NH had a percentage of stability of 53%, 
and the interactions with Cys241 and Leu255 were stable throughout the simulation 
time. The distance between the Cys241 SH and the closest methoxy group of the 
trimethoxyphenyl moiety was always less than 3.8 Å. 
This analysis brought out a hydrophobic interaction between the thiophen-2-yl 
nucleus and Lys254 side chain that was never observed for ATI derivatives bearing 
the ester functionality.134 In particular the δ and τ carbon atoms of Lys254 side chain 
lay to a bond distance from thiophen-2-yl centroid ring forming a stable 
hydrophobic interaction. From dynamic simulations, Leu248 played an important 
role in the stabilization of the trimethoxyphenyl moiety rather than of the 
heterocycle (RMSD = 1.70 Å for the tubulin α carbon atoms; 0.67 Å for derivative 
90) (Figure 27). 
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Figure 27. Snapshot of tubulin/compound 90 (pink) trajectories. H-bonds are reported as yellow 
dotted lines. Residues of the binding site and GTP are also reported as lines. 
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8. Conclusions 
New ATIs were designed and synthesized by bioisosteric replacement of both 
sulphur bridge and ester function. 114-115 
The replacement of the sulphur atom with a carbonyl group led to compounds 
endowed with comparable inhibition of tubulin assembly, while the introduction of a 
methylene moiety led to inhibitors of tubulin assembly whose potency was 
dependent on the substituent at position 2 of the indole ring. However, as inhibitors 
of the growth of MCF-7 human breast carcinoma cells, sulphur derivatives were 
superior or equivalent to the ketones, while methylene derivatives were generally 
less effective. Compounds bearing either a bromine atom or a methoxy group at 
position 5 and the 2-methoxycarbonyl group at position 2 of the indole ring were 
potent inhibitors of both tubulin polymerization and MCF-7 cell growth, with 
potencies comparable to those of CSA4 (22). The most active esters showed ~50% 
inhibition of human HeLa and HCT116/chr3 cell growth at 0.5 μM, and these 
compounds also reduced cell viability of HEK, M14 and U937 cells, with IC50’s in 
the 78-220 nM range. In contrast, murine macrophage J744.1 cell growth was 
significantly less affected (20% at the highest concentrations). 
The ester function of ATIs was replaced with 5-membered heterocycle nucleus 
and aromatic group to improve the pharmacokinetics properties, because the ester 
function was rapidly hydrolyzed in the corresponding acid. The new synthesized 
ATIs were potent inhibitors of the tubulin polymerization and the efficacy was 
improved compared with the previously synthesized ester 42 and classical MT 
inhibitors used as reference compounds. In particular, the new ATIs 81, 90 and 91, 
bearing a pyrrole and thiophene moiety, showed a valuable biological profile: (i) 
they were potent tubulin polymerization inhibitors in the low/submicromolar range 
of concentration; (ii) such compounds were uniformly more active in the Pgp-
overexpressing NCI/ADR-RES cell line than in the parental OVCAR-8 line and 
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were superior to VRB, VBL and PTX; (iii) compounds 81 and 91 showed selective 
activity against cells with acquired cisplatin resistance; (iv) they reduced cell growth 
in a panel of human transformed cell lines via arrest of mitotic progression and 
induction of cell death; (v) the induction of mitotic arrest in cell populations treated 
with these ATIs was in the same range as was observed with CSA4 and VBL; (vi) 
they induced apoptosis in the same range or above the level induced by VBL and 
CSA4, and triggered caspase-3 activation; (vii) the sulphur bridging group of ATIs 
showed satisfactory metabolic stability. We would like to highlight their 
effectiveness in HeLa and MDA-231 cell lines, both of which lack functional p53: 
this indicates that the cell death pathway triggered by ATIs is p53-independent.  
This is of relevance from a therapeutic perspective, given that about 50% of all 
human tumors are defective for p53 function and cannot respond to DNA-targeting 
drugs, which induce p53-dependent apoptosis. On the whole, the present data, 
strongly support the therapeutic potential and further development of the new ATIs. 
Finally, the metabolic stability data of compound 81, obtained both in mouse and 
human microsomes, concurrently to the excellent mouse pharmacokinetic profile, 
warrant further in vivo efficacy experiments. 
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9. Experimental section  
 
9.1 Chemistry.  
MW-assisted reactions were performed on Discover LabMate (CEM), setting 
temperature, irradiation power, maximum pressure (Pmax), PowerMAX (in situ 
cooling during the MW irradiation), ramp and hold times, and open and closed 
vessel modes as indicated. Melting points (mp) were determined on a Büchi 510 
apparatus and are uncorrected. Infrared spectra (IR) were run on a SpectrumOne FT 
spectrophotometer. Band position and absorption ranges are given in cm-1. Proton 
nuclear magnetic resonance (1H NMR) spectra were recorded on Bruker 400 MHz 
FT spectrometers in the indicated solvent. Chemical shifts are expressed in δ units 
(ppm) from tetramethylsilane. Column chromatography was performed on columns 
packed with alumina from Merck (70-230 mesh) or silica gel from Macherey-Nagel 
(70-230 mesh). Aluminum oxide TLC cards from Fluka (aluminum oxide precoated 
aluminum cards with fluorescent indicator visualizable at 254 nm) and silica gel 
TLC cards from Macherey-Nagel (silica gel precoated aluminum cards with 
fluorescent indicator visualizable at 254 nm) were used for thin layer 
chromatography (TLC). Developed plates were visualized by a Spectroline ENF 
260C/F UV apparatus. Organic solutions were dried over anhydrous sodium sulfate. 
Evaporation of the solvents was carried out on a Büchi Rotavapor R-210 equipped 
with a Büchi V-850 vacuum controller and Büchi V-700 and V-710 vacuum pumps. 
Elemental analyses of the biologically tested compounds were found within ± 0.4% 
of the theoretical values. Purity of tested compounds was >95%. Compounds 36115, 
39113, 42113, 45115, 48113, 51114, 57115, 66115, 69113 and 75114 were prepared as 
previously reported. 2-Phenyl-1H-indole was purchased by Sigma Aldrich. 
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9.2 Synthesis. 
General Procedure for the Synthesis of Compounds 37, 40, 43, 46, 49, 52, 58, 
61, 64, 67, 72, 76, 85, 88, 91, 94, 97, 106, 109 and 137. Example: (1H-Indol-3-yl)-
(3,4,5-trimethoxyphenyl)methanone (37). A mixture of AlCl3 (0.57 g; 0.0043 mol), 
1H-indole (0.5 g, 0.0043 mol) and 3,4,5-trimethoxybenzoyl chloride (0.99 g, 0.0043 
mol) in 1,2-dichloroethane (2 mL) was placed into the MW cavity (closed vessel 
mode, Pmax = 250 PSI). MW irradiation of 150 W was used, the temperature being 
ramped from 25 °C to 110 °C, while stirring. Once 110 °C was reached, taking 
about 1 min, the reaction mixture was held at this temperature for 2 min, then cooled, 
diluted cautiously with water, and extracted with chloroform; the organic layer was 
washed with brine, dried and filtered. Removal of the solvent gave a residue that 
was purified by silica gel column chromatography (ethyl acetate:n-hexane = 1:1 as 
eluent) to furnish 37 as a white solid (0.71 g, 53%), mp 210-213 °C (from ethanol), 
differing from lit.135 174-176 °C and lit.136 132-133 °C. 1H NMR (DMSO-d6): δ 3.73 
(s, 3H), 3.83 (s, 6H), 7.06 (s, 2H), 7.20-7.24 (m, 2H), 7.48 (d, J = 9.1 Hz, 1H), 8.06 
(d, J = 3.0 Hz, 1H), 8.21 (d, J = 8.5 Hz, 1H), 11.99 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR: ν 1571, 3179 cm-1. Anal calcd for C18H17NO4 (311,33) 
C, 69.44; H, 5.50; N, 4.50; found: C, 69.43; H, 5.48; N, 4.51. 
Methyl 3-(3,4,5-trimethoxybenzoyl)-1H-indole-2-carboxylate (40). Was 
synthesized as 37, starting from methyl 1H-indole-2-carboxylate, yield 55%, yellow 
solid, mp 163-168 °C (from ethanol/water). 1H NMR (DMSO-d6): δ 3.52 (s, 3H), 
3.73 (s, 6H), 3.74 (s, 3H), 7.03 (s, 2H), 7.17 (t, J = 7.2 Hz, 1H), 7.34 (t, J = 7.2 Hz, 
1H), 7.54 (d, J = 7.5 Hz, 1H), 7.60 (d, J = 7.3 Hz, 1H), 12.56 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR: ν 1634, 1710, 3279 cm-1. Anal calcd 
for C20H19NO6 (369.37) C, 65.02; H, 5.19; N, 3.79; found: C, 65.01; H, 5.18; N, 
3.79. 
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Ethyl 3-(3,4,5-trimethoxybenzoyl)-1H-indole-2-carboxylate (43). Was 
synthesized as 37, starting from ethyl 5-methoxy-1H-indole-2-carboxylate, yield 
39%, white solid, mp 105-110 °C (ethanol/n-hexane). 1H NMR (CDCl3): δ 1.01 (t, J 
= 7.1 Hz, 3H), 3.82 (s, 6H), 3.93 (s, 3H), 4.14 (q, J = 7.1 Hz, 2H), 7.18 (s, 2H), 7.24 
(t, J = 7.1 Hz, 1H), 7.41 (t, J = 7.1 Hz, 1H), 7.5 (d, J = 8.3 Hz, 1H), 7.73 (d, J = 8.1 
Hz, 1H), 9.26 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1648, 
1686, 3303 cm-1. Anal calcd for C21H21NO6 (383.39) C, 65.77; H, 5.52; N, 3.65; 
found: C, 65.77; H, 5.53; N, 3.64. 
(5-Chloro-1H-indol-3-yl)-(3,4,5-trimethoxyphenyl)methanone (46). Was 
synthesized as 37, starting from 5-chloro-1H-indole, yield 68%, white solid, mp 
240-245 °C (from ethanol). 1H NMR (DMSO-d6): δ 3.76 (s, 3H), 3.86 (s, 6H), 7.09 
(s, 2H), 7.28 (dd, J = 8.7 Hz, 1H), 7.54 (t, J = 8.1 Hz, 1H), 8.19 (s, 1H), 8.23 (d, J = 
2.2 Hz, 1H), 12.21 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 
1600, 3261 cm-1. Anal calcd for C18H16ClNO4 (345.78) C, 65.29; H, 4.67; Cl, 10.13; 
N, 4.06; found: C, 65.30; H, 4.67; Cl, 10.14; N, 4.05. 
Methyl 5-chloro-3-(3,4,5-trimethoxybenzoyl)-1H-indole-2-carboxylate (49). 
Was synthesized as 37, starting from methyl 5-chloro-1H-indole-2-carboxylate, 
yield 68%, yellow solid, mp 188-193 °C (from ethanol/water). 1H NMR (CDCl3): δ 
3.69 (s, 3H), 3.84 (s, 6H), 3.96 (s, 3H), 7.16 (s, 2H), 7.36 (dd, J = 8.8 Hz, 1H), 7.44 
(t, J = 8.8 Hz, 1H), 7.66 (d, J = 1.9  Hz, 1H), 9.50 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR: ν 1645, 1711, 3259 cm-1. Anal calcd for C20H18ClNO6 
(403.81) C, 59.54; H, 4.50; Cl, 8.67; N, 3.47; found: C, 59.53; H, 4.51; Cl, 8.66; N, 
3.47. 
Ethyl 5-chloro-3-(3,4,5-trimethoxybenzoyl)-1H-indole-2-carboxylate (52). 
Was synthesized as 37, starting from ethyl 5-chloro-1H-indole-2-carboxylate, yield 
38%, yellow solid, mp 160-163 °C (from ethanol). 1H NMR (DMSO-d6): δ 0.86 (t, J 
= 7.1 Hz, 3H), 3.73 (s, 3H), 3.75 (s, 6H), 3.96 (q, J = 7.1 Hz, 2H), 7.04 (s, 2H), 7.38 
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(dd, J = 10.1 Hz, 1H), 7.58 (d, J = 7.4 Hz 1H), 7.69 (d, J = 2.1 Hz, 1H), 12.78 ppm 
(broad s, disappeared on treatment with D2O, 1H). IR: ν 1636, 1684, 3294 cm-1. 
Anal calcd for C21H20ClNO6 (417.84) C, 60.42; H, 4.83; Cl, 8.38; N, 3.36; found: C, 
60.44; H, 4.83; Cl, 8.37; N, 3.35. 
Ethyl 5-chloro-3-(2-(3,4,5-trimethoxyphenyl)acetyl)-1H-indole-2-carboxylate 
(54). Was synthesized as 37, starting from ethyl 5-chloro-1H-indole-2-carboxylate 
and 2-(3,4,5-trimethoxyphenyl)acetyl chloride, yield 32%, yellow solid, mp 129-
134 °C (from ethanol). 1H NMR (CDCl3): δ 1.46 (t, J = 7.1 Hz, 3H), 3.80 (s, 6H), 
3.83 (s, 3H), 4.40 (s, 2H), 4.50 (q, J = 7.1 Hz, 2H), 6.46 (s, 2H), 7.32 (dd, J = 8.8 
Hz, 1H), 7.33 (dd, J = 9.5 Hz, 1H), 7.96 (d, J = 1.8 Hz, 1H), 9.22 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR: ν 1641, 1721, 3169 cm-1. Anal calcd 
for C22H22ClNO6 (431.87) C, 61.24; H, 5.14; Cl, 8.11; N, 3.25; found: C, 61.25; H, 
5.13; Cl, 8.11; N, 3.26. 
(5-Bromo-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (58). Was 
synthesized as 37, starting from 5-bromo-1H-indole, yield 53%, yellow solid, mp 
235-240 °C (from ethanol). 1H NMR (DMSO-d6): δ 3.76 (s, 3H), 3.86 (s, 6H), 7.09 
(s, 2H), 7.40 (dd, J = 6.6 Hz, 1H), 7.50 (d, J = 8.1 Hz, 1H), 8.18 (s, 1H), 8.39 (d, J 
= 2.5 Hz, 1H), 12.19 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 
1599, 3279 cm-1. Anal calcd for C18H16BrNO4 (390.23) C, 55.52; H, 4.14; Br, 20.28; 
N, 3.59; found: C, 55.51; H, 4.13; Br, 20.28; N, 3.59. 
Methyl 5-bromo-3-(3,4,5-trimethoxybenzoyl)-1H-indole-2-carboxylate (61). 
Was synthesized as 37, starting from 124, yield 40%, white solid, mp 207-210 °C 
(from ethanol/n-hexane). 1H NMR (CDCl3): δ 3.68 (s, 3H), 3.83 (s, 6H), 3.95 (s, 3H), 
7.14 (s, 2H), 7.38 (d, J = 8.2 Hz, 1H), 7.48 (dd, J = 6.9 Hz, 1H), 7.81 (d, J = 1.8 Hz, 
1H), 9.45 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1642, 1711, 
3248 cm-1. Anal calcd for C20H18BrNO6 (448.26) C, 53.69; H, 4.06; Br, 17.65; N, 
3.13; found: C, 53.69; H, 4.07; Br, 17.64; N, 3.14. 
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Ethyl 5-bromo-3-(3,4,5-trimethoxybenzoyl)-1H-indole-2-carboxylate (64). 
Was synthesized as 37, starting from 117, yield 46%, yellow solid, mp 135-140 °C 
(from ethanol/n-hexane). 1H NMR (DMSO-d6): δ 0.85 (t, J = 7.1 Hz, 3H), 3.73 (s, 
3H), 3.75 (s, 6H), 3.98 (q, J = 7.1 Hz, 2H), 7.03 (s, 2H), 7.33 (d, J = 1.2 Hz, 1H), 
7.48 (dd, J = 6.9 Hz, 1H), 7.53 (dd, J = 8.8 Hz, 1H), 12.74 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR: ν 1638, 1702, 3292 cm-1. Anal calcd 
for C21H20BrNO6 (462.29) C, 54.66; H, 4.37; Br, 17.12; N, 3.04; found: C, 54.65; H, 
4.36; Br, 17.12; N, 3.04. 
(5-Methoxy-1H-indol-3-yl)-(3,4,5-trimethoxyphenyl)methanone (67). Was 
synthesized as 37, starting from 5-methoxy-1H-indole, yield 42%, yellow solid, mp 
202-207 °C (from ethanol), lit.117 194-195 °C. 
Methyl 5-methoxy-3-(3,4,5-trimethoxybenzoyl)-1H-indole-2-carboxylate (72). 
Was synthesized as 37, starting from methyl 5-methoxy-1H-indole-2-carboxylate, 
yield 20%, yellow solid, mp 168-173 °C (from ethanol/water). 1H NMR (DMSO-d6): 
δ 3.47 (s, 3H), 3.71 (s, 3H), 3.73 (s, 3H), 3.74 (s, 6H), 6.99-7.02 (m, 3H), 7.07 (d, J 
= 2.3 Hz, 1H), 7.44 (d, J = 8.95 Hz, 1H), 12.49 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR: ν 1635, 1710, 3274 cm-1. Anal calcd for C21H21NO7 
(399.39) C, 63.14; H, 5.30; N, 3.51; found: C, 63.13; H, 5.31; N, 3.51. 
Ethyl 5-methoxy-3-(3,4,5-trimethoxybenzoyl)-1H-indole-2-carboxylate (76). 
Was synthesized as 37, starting from ethyl 5-methoxy-1H-indole-2-carboxylate, 
yield 60%, yellow solid, mp 150-155 °C (from ethanol). 1H NMR (CDCl3): δ 0.97 (t, 
J = 7.1 Hz, 3H), 3.82 (s, 3H), 3.84 (s, 6H), 3.94 (s, 3H), 4.09 (q, J = 7.1 Hz, 2H), 
7.07 (dd, J = 6.5 Hz, 1H), 7.18 (s, 2H), 7.26 (d, J = 1.9 Hz, 1H), 7.39 (d, J = 9.0 Hz, 
1H), 9.21 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1647, 1694, 
3353 cm-1. Anal calcd for C22H23NO7 (413.42) C, 63.90; H, 5.61; N, 3.39; found: C, 
63.91; H, 5.62; N, 3.40. 
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(2-(Furan-2-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (85). Was 
synthesized as 37, starting from 118, yield 6%, yellow solid, mp 115-117 °C (from 
ethanol). 1H NMR (CDCl3): δ 3.80 (s, 6H), 3.95 (s, 3H), 6.50-6.51 (m, 1H), 7.10-
7.15 (m, 3H), 7.22-7.26 (m, 2H), 7.41-7.46 (m, 2H), 7.52-7.53 (m, 1H), 9.11 ppm 
(broad s, disappeared on treatment with D2O, 1H). IR: ν 3358 cm-1. Anal calcd. for 
C22H19NO5 (377,39) C, 70.02; H, 5.07; N, 3.71; found: C, 70.02; H, 5.06; N, 3.73. 
(2-(Furan-3-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (88). Was 
synthesized as 37, starting from 130, yield 32%, yellow oil. 1H NMR (CDCl3): δ 
3.78 (s, 6H), 3.93 (s, 3H), 6.60-6.61 (m, 1H), 7.13 (s, 2H), 7.15-7.19 (m, 1H), 7.25-
7.27 (m, 1H), 7.43-7.46 (m, 2H), 7.58-7.60 (m, 1H), 8.05-8.06 (m, 1H), 8.70 ppm 
(broad s, disappeared on treatment with D2O, 1H). IR: ν 3349 cm-1. Anal calcd. for 
C22H19NO5 (377,39) C, 70.02; H, 5.07; N, 3.71; found: C, 70.01; H, 5.05; N, 3.72. 
(2-(Thiophen-2-yl)-1H-indol-3-yl)-(3’,4’,5’-trimethoxyphenyl)methanone 
(91). Was synthesized as 37, starting from 133, yield 34%, yellow solid, mp 155-
159 °C (from ethanol). 1H NMR (DMSO-d6): δ 3.75 (s, 6H), 3.88 (s, 3H), 6.96-6.98 
(m, 1H), 7.08 (s, 2H), 7.20-7.24 (m, 2H), 7.30-7.34 (m, 2H), 7.45 (d, J = 8.0 Hz, 1H), 
7.80 (d, J = 7.8 Hz, 1H), 8.73 ppm (broad s, disappeared on treatment with D2O, 1H). 
IR: ν 1570, 3214 cm-1. Anal calcd. for C22H19NO4S (393.46) C, 67.16; H, 4.87; N, 
3.56; found: C, 66.92; H, 4.79; N, 3.41. 
(2-(Thiophen-3-yl)-1H-indol-3-yl)-(3’,4’,5’-trimethoxyphenyl)methanone 
(94). Was synthesized as 37, starting from 134, yield 25%, yellow solid, mp 118-
120 °C (from ethanol). 1H NMR (CDCl3): δ 3.74 (s, 6H), 3.87 (s, 3H), 7.04 (s, 2H), 
7.11-7.12 (m, 1H), 7.23-7.28 (m, 2H), 7.29-7.33 (m, 1H), 7.44-7.47 (m, 1H), 7.50-
7.51 (m, 1H), 7.91-7.93 (m, 1H), 8.60 ppm (broad s, disappeared on treatment with 
D2O, 1H). IR: ν 3337 cm-1. Anal calcd. for C22H19NO4S (393.46) C, 67.16; H, 4.87; 
N, 3.56; found: C, 66.95; H, 4.81; N, 3.43. 
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(2-Phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (97). Was 
synthesized as 37, starting from 2-phenyl-1H-indole, yield 95%, grey solid, mp 207-
212 °C (from ethanol). 1H NMR (DMSOd6): δ 3.59 (s, 3H), 3.60 (s, 6H), 6.82 (s, 
2H), 7.18-7.28 (m, 5H), 7.36-7.38 (m, 2H), 7.50-7.53 (m, 1H), 7.92-7.94 (m, 1H), 
12.20 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 3213 cm-1. Anal 
calcd. for C24H21NO4 (387,43) C, 74.40; H, 5.46; N, 3.62; found: C, 74.36; H, 5.41; 
N, 3.59. 
(2-(Naphthalen-1-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone 
(106). Was synthesized as 37, starting from 136, yield 50%, white solid, mp 177-
179 °C (from ethanol). 1H NMR (CDCl3): δ 3.40 (s, 6H), 3.64 (s, 3H), 6.61 (s, 2H), 
7.26-7.30 (m, 1H), 7.34-7.36 (m, 1H), 7.37-7.41 (m, 2H), 7.43-7.53 (m, 3H), 7.73 (d, 
J = 8.2 Hz, 1H), 7.78-7.83 (m, 1H), 7.94-8.00 (m, 1H), 8.31-8.36 (m, 1H), 8.81 ppm 
(broad s, disappeared on treatment with D2O, 1H). IR: ν 3158 cm-1. Anal calcd. for 
C28H23NO4 (437,49) C, 76.87; H, 5.30; N, 3.20; found: C, 76.81; H, 5.24; N, 3.17. 
(2-(Naphthalen-2-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone 
(109). Was synthesized as 37, starting from 122, yield 33%, yellow solid, mp 182-
186 °C (from ethanol). 1H NMR (CDCl3): δ 3.56 (s, 3H), 3.63 (s, 6H), 6.98 (s, 2H), 
7.29-7.37 (m, 2H), 7.43 (dd, J = 8.5 and 1.8 Hz, 1H), 7.47-7.52 (m, 3H), 7.68-7.78 
(m, 3H), 7.87 (m, 1H), 8.10-8.11 (m, 1H), 8.80 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR: ν 3170 cm-1. Anal calcd. for C28H23NO4 (437,49) C, 
76.87; H, 5.30; N, 3.20; found: C, 76.78; H, 5.22; N, 3.15.  
(2-(1-(Phenylsulfonyl)-1H-pyrrol-3-yl)-1H-indol-3-yl)(3,4,5-
trimethoxyphenyl)methanone (137). Was synthesized as 37, starting from 128, 
yield 64%, green solid, mp 124-126 °C (from ethanol). 1H NMR (CDCl3): δ 3.71 (s, 
6H), 3.91 (s, 3H), 6.48-6.49 (m, 1H), 7.08-7.17 (m, 4H), 7.22-7.28 (m, 1H), 7.39-
7.40 (m, 1H), 7.51-7.66 (m, 5H), 7.83-7.85 (m, 2H), 8.76 ppm (broad s, disappeared 
on treatment with D2O, 1H). IR: ν 3284 cm-1. 
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(2-(1H-Pyrrol-3-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (82). 
A mixture of 137 (0.1 g, 0.00019 mol) and 2N NaOH (0.59 mL) in MeOH (1.7 mL) 
was heated at 70 °C for 3 h. After cooling 2 N HCl was added and the mixture was 
extracted wiyh AcOEt; organic layer was washed with brine, dried and filtered. 
Removal of the solvent gave a residue that was purified by silica gel column 
chromatography (ethyl acetate : n-exane = 1:1 as eluent) to furnish 82 as a yellow 
solid (0.07 g, 98%), mp 114-115 °C (from ethanol). 1H NMR (CDCl3): δ 3.77 (s, 
6H), 3.90 (s, 3H), 6.42-6.44 (m, 1H), 6.77-6.79 (m, 1H), 7.10 (s, 2H), 7.14-7.25 (m, 
3H), 7.40-7.42 (m, 1H), 7.67-7.71 (m, 1H), 8.38 (broad s, disappeared on treatment 
with D2O, 1H), 8.53 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 
3241, 3333 cm-1. Anal calcd. for C22H20N2O4  (376,41) C, 70.20; H, 5.36; N, 7.44; 
found: C, 70.19; H, 5.35; N, 7.45. 
General Procedure for the Synthesis of Compounds 80, 100, 102 and 104. 
Example: (2-(1H-Pyrrol-2-yl)-1H-indol-3-yl)(3,4,5-
trimethoxyphenyl)methanone (80). To a mixture of 126 (0.5 g, 0.003 mol) and 
anhydrous ZnCl2 (0.818 g, 0.006 mol) in anhydrous CH2Cl2 (20 mL), CH3MgBr 
(3M diethylether solution) (1.3 mL, 0.0041 mol) was added dropwise at 25 °C and 
under Ar stream. The resulting suspension was stirred for 1 h and to it a solution of 
3,4,5-trimethoxybenzoylchloride (0.76 g, 0.0033 mol) in anhydrous CH2Cl2 (16 mL) 
was added dropwise over 5 min at 25 °C. The resulting mixture was stirred for 1 h 
followed by addition of SnCl4 (1M dichloromethane solution) (3 mL, 0.003 mol). 
The resulting mixture was stirred overnight at 25 °C, then quenched on bath ice and 
extracted with dichloromethane; organic layer was washed with brine, dried and 
filtered. Removal of the solvent gave a residue that was twice purified by silica gel 
column chromatography (ethyl acetate : n-exane = 1:1 and ethyl acetate : n-exane = 
1.2 as eluents) to furnish 80 as a green solid (0.03 g, 3%), mp 55-60 °C (from 
ethanol). 1H NMR (DMSOd6): δ 3.70 (s, 6H), 3.75 (s, 3H), 6.24-6.26 (m, 1H), 6.84-
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6.85 (m, 1H), 6.96-7.07 (m, 5H), 7.14-7.18 (m, 1H), 7.43-7.45 (m, 1H), 11.94 
(broad s, disappeared on treatment with D2O, 1H), 12.15 ppm (broad s, disappeared 
on treatment with D2O, 1H). IR: ν 3235, 3328 cm-1. Anal calcd. for C22H20N2O4  
(376,41) C, 70.20; H, 5.36; N, 7.44; found: C, 70.18; H, 5.36; N, 7.46. 
(2-(Pyridin-2-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (100). 
Was synthesized as 80 starting from 119, yield 67%, yellow solid, mp 65-70 °C 
(from ethanol). 1H NMR (DMSOd6): δ 3.61 (s, 6H), 3.64 (s, 3H), 6.89 (s, 2H), 7.19-
7.21 (m, 1H), 7.26-7.28 (m, 2H), 7.39-7.41 (m, 1H), 7.56-7.58 (m, 1H), 7.63-7.65 
(m, 1H), 7.79-7.81 (m, 1H), 8.55-8.57 (m, 1H), 12.36 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR: ν 3241 cm-1. Anal calcd. for C23H20N2O4 (388.42) C, 
71.12; H, 5.19; N, 7.21; found: C, 71.07; H, 5.15; N, 7.19. 
(2-(Pyridin-3-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (102). 
Was synthesized as 80 starting from 120, yield 45%, yellow solid, mp 130-135 °C 
(from ethanol). 1H NMR (DMSOd6): δ 3.60 (s, 3H), 3.61 (s, 6H), 6.82 (s, 2H), 7.21-
7.31 (m, 3H), 7.53-7.55 (m, 1H), 7.75-7.78 (m, 1H), 7.96 (d, J = 7.7 Hz, 1H), 8.44 
(dd, J = 4.8 and 1.6 Hz, 1H), 8.56-8.57 (m, 1H), 12.38 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR: ν 3094 cm-1. Anal calcd. for C23H20N2O4 (388.42) C, 
71.12; H, 5.19; N, 7.21; found: C, 71.09; H, 5.17; N, 7.20. 
(2-(Pyridin-4-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (104). 
Was synthesized as 80 starting from 121, yield 10%, yellow solid, mp 50-55 °C 
(from ethanol). 1H NMR (DMSOd6): δ 3.62 (s, 3H), 3.63 (s, 6H), 6.86 (s, 2H), 7.21-
7.25 (m, 1H), 7.29-7.33 (m, 1H), 7.35-7.37 (m, 2H), 7.55-7.57 (m, 1H), 7.87-7.90 
(m, 1H), 8.46-8.47 (m, 2H), 12.43 ppm (broad s, disappeared on treatment with D2O, 
1H). IR: ν 3179 cm-1. Anal calcd. for C23H20N2O4 (388.42) C, 71.12; H, 5.19; N, 
7.21; found: C, 71.05; H, 5.13; N, 7.18. 
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General Procedure for the Synthesis of Compounds 38, 47, 59, 68 and 92. 
Example: 3-(3,4,5-trimethoxybenzyl)-1H-indole (38). Sodium borohydride (0.80 g, 
0.021 mol) was added to a solution of 37 (0.66 g, 0.0021 mol) in ethanol (85 mL). 
The reaction mixture was refluxed for 3 h, then cooled, cautiously diluted with water 
and extracted with ethyl acetate; the organic layer was washed with brine, dried and 
filtered. Evaporation of the solvent gave a residue that was purified by silica gel 
column chromatography (ethyl acetate:n-hexane = 1:1 as eluent) to furnish 38 as a 
white solid (0.26 g, 42%), mp 133-136 °C (from ethanol), lit.135 125-126 °C and 
lit.137 128-130 °C. 
5-Chloro-3-(3,4,5-trimethoxybenzyl)-1H-indole (47). Was synthesized as 38 
starting from 46, yield 47%, orange solid, mp 145-150 °C (from ethanol). 1H NMR 
(CDCl3): δ 3.80 (s, 6H), 3.83 (s, 3H), 4.00 (s, 2H), 6.49 (s,  2H), 6.95 (d, J = 2.3 Hz, 
1H), 7.14 (dd, J = 8.6 Hz, 1H), 7.28 (d, J = 8.1 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 
8.40 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 3372 cm-1. Anal 
calcd for C18H18ClNO3 (331.79) C, 65.24; H, 5.48; Cl, 10.56; N, 4.23; found: C, 
65.24; H, 5.49; Cl, 10.58; N, 4.21. 
5-Bromo-3-(3,4,5-trimethoxybenzyl)-1H-indole (59). Was synthesized as 38, 
starting from 58, yield 58%, white solid, mp 145-150 °C (from ethanol). 1H NMR 
(CDCl3): 3.81 (s, 6H), 3.84 (s, 3H), 4.01 (s, 2H), 6.50 (s, 2H), 6.94 (d, J = 2.3 Hz, 
1H), 7.24-7.28 (m, 2H), 7.69 (d, J = 1.7 Hz, 1H), 8.05 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR: ν 3353 cm-1. Anal calcd for C18H18BrNO3 (376,24) C, 
57.59; H, 4.84; Br, 21.04; N, 3.73; found: C, 57.60; H, 4.85; Br, 21.04; N, 3.73. 
5-Methoxy-3-(3,4,5-trimethoxybenzyl)-1H-indole (68). Was synthesized as 38, 
starting from 67, yield 68%, white solid, mp 110-113 °C (from ethanol). 1H NMR 
(CDCl3): δ 3.78 (s, 6H), 3.80 (s, 3H), 3.81 (s, 3H), 4.01 (s, 2H), 6.51 (s, 2H), 6.84 (d, 
J = 8.8 Hz, 1H), 6.88 (t, J = 2.4 Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 7.24 (t, J = 4.7 
Hz, 1H), 7.90 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 3365 
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cm-1. Anal calcd for C19H21NO4 (327.37) C, 69.69; H, 6.47; N, 4.28; found: C, 69.69; 
H, 6.48; N, 4.29. 
2-(Thiophen-2-yl)-3-(3’,4’,5’-trimethoxybenzyl)-1H-indole (92) Was 
synthesized as 38, starting from 91, yield 21%, brown solid, mp 43-47 °C (from 
ethanol). 1H NMR (CDCl3): δ 3.73 (s, 6H), 3.80 (s, 3H), 4.27 (s, 2H), 6.47 (s, 2H), 
7.07-7.13 (m, 2H), 7.19-7.23 (m, 2H), 7.35-7.39 (m, 2H), 7.49 (d, J = 7.9 Hz, 1H), 
8.17 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 3340 cm-1. Anal 
calcd. for C22H21NO3S (379.47) C, 69.63; H, 5.58; N, 3.69; found: C, 69.41; H, 5.55; 
N, 3.50. 
General Procedure for the Synthesis of Compounds 41, 44, 50, 53, 56, 62, 65, 
74, and 78. Example: Methyl 3-(3,4,5-trimethoxybenzyl)-1H-indole-2-
carboxylate (41). To a cold solution of 40 (0.31 g, 0.00084 mol) in trifluoroacetic 
acid (0.96 g, 0.65 mL, 0.0084 mol) was added dropwise triethylsilane (0.22 g, 0.30 
mL, 0.0019 mol). The reaction mixture was stirred at 25 °C for 24 h, then 
neutralized with a saturated solution of sodium hydrogen carbonate and extracted 
with ethyl acetate; the organic layer was washed with brine, dried and filtered. 
Removal of the solvent gave a residue that was purified by silica gel column 
chromatography (ethyl acetate:n-hexane = 3:2 as eluent) to furnish 41 as a yellow 
solid (0.15 g, 50%), mp 156-161 °C (from ethanol/n-hexane). 1H NMR (CDCl3): δ 
3.69 (s, 6H), 3.72 (s, 3H), 3.89 (s, 3H), 4.38 (s, 2H), 6.46 (s, 2H), 7.05 (t, J = 8.1 Hz, 
1H), 7.25 (t, J = 8.3 Hz, 1H), 7.33 (d, J = 7.4 Hz, 1H), 7.57 (d, J = 8.2 Hz, 1H), 
8.75 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1690, 3318 cm-1. 
Anal calcd for C20H21NO5 (355.38) C, 67.58; H, 5.95; N, 3.94; found: C, 67.57; H, 
5.95; N, 3.92. 
Ethyl 3-(3,4,5-trimethoxybenzyl)-1H-indole-2-carboxylate (44). Was 
synthesized as 41, starting from 43, yield 73%, white solid, mp 115-118 °C (from 
ethanol/n-hexane). 1H NMR (CDCl3): δ 1.42 (t, J = 7.1 Hz, 3H), 3.77 (s, 6H), 3.80 
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(s, 3H), 4.44 (q, J = 7.1 Hz, 2H), 4.47 (s, 2H), 6.55 (s, 2H), 7.13 (t, J = 7.0 Hz, 1H), 
7.33 (t, J = 6.9 Hz, 1H), 7.39 (d, J = 7.5 Hz, 1H), 7.64 (d, J = 7.4 Hz, 1H), 8.82 
ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1672, 3337 cm-1. Anal 
calcd for C21H23NO5 (369.41) C, 68.23; H, 6.28; N, 3.79; found: C, 68.22; H, 6.25; 
N, 3.79. 
Methyl 5-chloro-3-(3,4,5-trimethoxybenzyl)-1H-indole-2-carboxylate (50). 
Was synthesized as 41, starting from 49, yield 69%, white solid, mp 172-175 °C 
(from ethanol/n-hexane). 1H NMR (CDCl3): δ 3.70 (s, 6H), 3.73 (s, 3H), 3.89 (s, 3H), 
4.33 (s, 2H), 6.42 (s, 2H), 7.21 (d, J = 1.9 Hz, 1H), 7.24 (t, J = 8.7 Hz, 1H), 7.51 (d, 
J = 1.9 Hz, 1H), 8.74 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 
1682, 3322 cm-1. Anal calcd for C20H20ClNO5 (389.83) C, 61.68; H, 5.18; Cl, 8.99; 
N, 3.60; found: C, 61.69; H, 5.17; Cl, 8.98; N, 3.60. 
Ethyl 5-chloro-3-(3,4,5-trimethoxybenzyl)-1H-indole-2-carboxylate (53). Was 
synthesized as 41, starting from 52, yield 95%, yellow solid, mp 147-150 °C (from 
ethanol/n-hexane). 1H NMR (CDCl3): δ 1.41 (t, J = 7.1 Hz, 3H), 3.79 (s, 6H), 3.81 (s, 
3H), 4.41 (s, 2H), 4.43 (q, J = 6.4 Hz, 2H), 6.51 (s, 2H), 7.25-7.28 (m, 1H), 7.33 (dd, 
J = 8.1 Hz, 1H), 7.59-7.60 (m, 1H), 8.91 ppm (broad s, disappeared on treatment 
with D2O, 1H). IR: ν 1666, 3315 cm-1. Anal calcd for C21H22ClNO5 (417,84) C, 
62.51; H, 5.50; Cl, 8.67; N, 3.47; found: C, 62.51; H, 5.51; Cl, 8.66; N, 3.46. 
Ethyl 5-chloro-3-(3,4,5-trimethoxyphenethyl)-1H-indole-2-carboxylate (56). 
Was synthesized as 41, starting from 55, yield 40%, white solid, mp 163-165 °C 
(from ethanol). 1H NMR (CDCl3): δ 1.44 (t, J = 7.5 Hz, 3H), 2.88 (t, J = 7.4 Hz, 2H), 
3.35 (t, J = 7.3 Hz, 2H), 3.79 (s, 6H), 3.83 (s, 3H), 4.42 (t, J = 7.1 Hz, 2H), 6.38 (s, 
2H), 7.24 (dd, J = 9.2 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.49 (d, J = 1.9 Hz, 1H), 
9.01 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1669, 3318 cm-1. 
Anal calcd for C22H24ClNO5 (417.88) C, 62.29; H, 5.80; Cl, 8.38; N, 3.36; found: C, 
62.30; H, 5.81; Cl, 8.38; N, 3.36. 
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Methyl 5-bromo-3-(3,4,5-trimethoxybenzyl)-1H-indole-2-carboxylate (62). 
Was synthesized as 41, starting from 61, yield 97%, yellow solid, mp 177-182 °C 
(from ethanol/n-hexane). 1H NMR (DMSO-d6): δ 3.57 (s, 3H), 3.67 (s, 6H), 3.92 (s, 
3H), 4.34 (s, 2H), 6.62 (s, 2H), 7.36-7.36 (m, 2H), 7.90 (d, J = 2.3 Hz, 1H), 11.88 
ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1675, 3322 cm-1. Anal 
calcd for C20H20BrNO5 (434.28) C, 55.42; H, 4.65; Br, 18.22; N, 3.23; found: C, 
55.43; H, 4.64; Br, 18.22; N, 3.22. 
Ethyl 5-bromo-3-(3,4,5-trimethoxybenzyl)-1H-indole-2-carboxylate (65). Was 
synthesized as 41, starting from 64, yield 46%, white solid, mp 150-155 °C (from 
ethanol/n-hexane). 1H NMR (CDCl3): δ 1.41 (t, J = 7.1 Hz, 3H), 3.79 (s, 6H), 3.82 
(s, 3H), 4.43 (q, J = 7.1 Hz, 2H), 6.51 (s, 2H), 7.28 (d, J = 9.4 Hz, 1H), 7.29 (s, 2H), 
7.40 (dd, J = 6.9 Hz, 1H), 7.77 (d, J = 1.8 Hz, 1H), 8.90 ppm (broad s, disappeared 
on treatment with D2O, 1H). IR: ν 1665, 3317 cm-1. Anal calcd for C21H22BrNO6 
(448.31) C, 54.42; H, 7.79; Br, 17.04; N, 3.02; found: C, 54.43; H, 7.79; Br, 17.05; 
N, 3.02. 
Methyl 5-methoxy-3-(3,4,5-trimethoxybenzyl)-1H-indole-2-carboxylate (74). 
Was synthesized as 41, starting from 72, yield 58%, white solid, mp 125-128 °C 
(from ethanol/n-hexane). 1H NMR (CDCl3): δ 3.77 (s, 6H), 3.79 (s, 3H), 3.80 (s, 3H), 
3.94 (s, 3H), 4.42 (s, 2H), 6.53 (s, 1H), 6.96 (d, J = 2.3 Hz, 1H), 7.00 (dd, J = 6.4 
Hz, 1H), 7.28 (d, J = 8.9 Hz, 1H), 8.67 (s, 1H), 11.91 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:ν 1687, 3331 cm-1. Anal calcd for C21H23NO6 (385.41) 
C, 65.43; H, 6.01; N, 3.63; found: C, 65.44; H, 6.02; N, 3.63. 
Ethyl 5-methoxy-3-(3,4,5-trimethoxybenzyl)-1H-indole-2-carboxylate (78). 
Was synthesized as 41, starting from 76, yield 90%, white solid, mp 132-135 °C 
(from ethanol). 1H NMR (CDCl3): δ 1.42 (t, J = 7.1 Hz, 3H), 3.78 (s, 9H), 3.81 (s, 
3H), 4.44 (q, J = 7.2 Hz, 2H), 4.45 (s, 2H), 6.56 (s, 2H), 6.98-7.03 (m, 2H), 7.28-
7.32 (m, 1H), 8.76 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 
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1672, 3330 cm-1. Anal calcd for C22H25NO6 (399.44) C, 66.14; H, 6.31; N, 3.51; 
found: C, 66.13; H, 6.32; N, 3.50. 
General Procedure for the Synthesis of Compounds 73 and 77. Example: 
Methyl 3-(hydroxy(3,4,5-trimethoxyphenyl)methyl)-5-methoxy-1H-indole-2-
carboxylate (73). A mixture of 72 (0.34 g, 0.00085 mol) and sodium borohydride 
(0.03 g, 0.00085 mol) in THF (2.1 mL) and water (0.12 mL) was refluxed for 2 h. 
After cooling, water and ethyl acetate were added. The organic layer was removed 
and washed with brine, dried and filtered. Removal of the solvent gave a residue that 
was purified by silica gel column chromatography (ethyl acetate:n-hexane = 1:1 as 
eluent) to furnish 73 as a brown solid (0.1 g, 29% ), mp 100-103 °C (from ethanol). 
1H NMR (CDCl3): δ 3.76 (s, 3H), 3.79 (s, 6H), 3.82 (s, 3H), 3.97 (s, 3H), 4.53 (d, J 
= 1.2 Hz, 1H), 6.50 (d, J = 7.4 Hz, 1H), 6.77 (s, 2H), 6.95 (d, J = 2.4 Hz, 1H), 7.02 
(dd, J = 6.5 Hz, 1H), 7.28 (d, J = 8.4 Hz, 1H), 8.78 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR: ν 1707, 2937, 3322 cm-1. Anal calcd for C21H23NO7 
(401.41) C, 62.82; H, 5.78; N, 3.49; found: C, 62.83; H, 5.79; N, 3.49. 
Ethyl 3-(hydroxy(3,4,5-trimethoxyphenyl)methyl)-5-methoxy-1H-indole-2-
carboxylate (77). Was synthesized as 73, starting from 76, yield 53%, white solid, 
mp 115-120 °C (from ethanol). 1H NMR (CDCl3): δ 1.42 (t, J = 7.2 Hz, 3H), 3.76 (s, 
3H), 3.79 (s, 3H), 3.81 (s, 3H), 3.83 (s, 3H), 4.43 (q, J = 6.0 Hz, 2H), 4.44 (d, J = 
1.2 Hz, 1H), 6.49 (d, J = 7.2 Hz, 1H), 6.77 (s, 2H),  6.95 (d, J = 2.3 Hz, 1H), 7.01 
(dd, J = 6.6 Hz, 1H), 7.29 (d, J = 7.3 Hz, 1H), 8.78 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR: ν 1676, 3209, 3402 cm-1. Anal calcd for C22H25NO7 
(415.44) C, 63.59; H, 6.07; N, 3.37; found: C, 63.60; H, 6.06; N, 3.38. 
Ethyl 5-chloro-3-(2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl)-1H-indole-2-
carboxylate (55). A mixture of 54 (0.05 g, 0.00012 mol) and selenium(IV) oxide 
(0.05 g; 0.00045 mol) in DMSO (2 mL) was placed into the MW cavity (closed 
vessel mode, Pmax = 250 PSI). MW irradiation of 150 W was used, the temperature 
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being ramped from 25 °C to 150 °C. Once 150 °C was reached, taking about 1 min, 
the reaction mixture was held at this temperature for 2 min, while stirring, then 
cooled, diluted with water, and extracted with ethyl acetate; organic layer was 
washed with brine, dried and filtered. Removal of the solvent gave a residue that 
was purified by silica gel column chromatography (ethyl acetate:n-hexane = 1:2 as 
eluent) to furnish 55 as a yellow solid (0.03 g, 56%), mp 177-181 °C (from ethanol). 
1H NMR (CDCl3): δ 1.07(t, J = 7.2 Hz, 3H), 3.93 (s, 6H), 3.98 (s, 3H), 4.12 (q, J = 
7.1 Hz, 2H), 7.35 (s, 2H), 7.42-7.43 (m, 2H), 8.40 (s, 1H), 9.50 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR: ν 1650, 1672, 1724, 3275 cm-1. Anal 
calcd for C22H20ClNO7 (445.85) C, 59.31; H, 4.53; Cl, 7.86; N, 3.15; found: C, 
59.31; H, 4.54; Cl, 7.85; N, 3.14. 
General Procedure for the Synthesis of Compounds 86, 89, 95, 98, 107, 110 
and 138. Example: 2-(furan-2-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (86). To 
a cooled solution of 85 (0.07 g, 0.000185 mol) in CH3CN (1.09 mL) containing 
MeOH (0.017 mL) was added BH3-THF (1M, 0.8 mL) and the resulting mixture was 
stirred at 50 °C for 1 h. After cooling the mixture was diluted of water and extracted 
with AcOEt; organic layer was washed with brine, dried and filtered. Removal of the 
solvent gave a residue that was purified by silica gel column chromatography (ethyl 
acetate : n-hexane = 1:1 as eluent) to furnish 86 as brown solid (0.0062 g, 10%), mp 
78-80 °C (from ethanol). 1H NMR (CDCl3): δ 3.76 (s, 6H), 3.82 (s, 3H), 4.30 (s, 2H), 
6.51-6.55 (m, 4H), 7.09-7.13 (m, 1H), 7.21-7.24 (m, 1H), 7.40-7.43 (m, 1H), 7.52-
7.54 (m, 2H), 8.49 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 
3347 cm-1. Anal calcd. for C22H21NO4 (363,41) C, 72.71; H, 5.82; N, 3.85; found: C, 
72.69; H, 5.78; N, 3.84. 
2-(Furan-3-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (89). Synthesized as 86, 
starting from 88, yield 13% as a brown solid, mp 102-105 °C (from ethanol). 1H 
NMR (CDCl3): δ 3.73 (s, 6H), 3.80 (s, 3H), 4.18 (s, 2H), 6.44 (s, 2H), 6.65-6.66 (m, 
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1H), 7.07-7.11 (m, 1H), 7.17-7.19 (m, 1H), 7.37-7.39 (m, 1H), 7.47-7.49 (m, 1H), 
7.52-7.53 (m, 1H), 7.63-7.64 (m, 1H), 8.07 ppm (broad s, disappeared on treatment 
with D2O, 1H). IR: ν 3326 cm-1. Anal calcd. for C22H21NO4 (363,41) C, 72.71; H, 
5.82; N, 3.85; found: C, 72.67; H, 5.79; N, 3.86. 
2-(Thiophen-3-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (95). Synthesized as 
86, starting from 94, yield 61% as a yellow solid, mp 165-168 °C (from ethanol). 1H 
NMR (CDCl3): δ 3.74 (s, 6H), 3.83 (s, 3H), 4.25 (s, 2H), 6.48 (s, 2H), 7.10-7.14 (m, 
1H), 7.21-7.25 (m, 1H), 7.34-7.35 (m, 1H), 7.40-7.46 (m, 3H), 7.51-7.53 (m, 1H), 
8.22 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 3353 cm-1. Anal 
calcd. for C22H21NO3S (379.47) C, 69.63; H, 5.58; N, 3.69; found: C, 69.45; H, 5.54; 
N, 3.53. 
2-Phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (98). Synthesized as 86, 
starting from 97, yield 26% as a white solid, mp 187-192 °C (from ethanol). 1H 
NMR (DMSOd6): δ 3.59 (d, 9H), 4.17 (s, 2H), 6.46 (s, 2H), 6.97-7.01 (m, 1H), 7.09-
7.13 (m, 1H), 7.37-7.41 (m, 2H), 7.47-7.53 (m, 3H), 7.64-7.66 (m, 2H), 11.28 ppm 
(broad s, disappeared on treatment with D2O, 1H). IR: ν 3351 cm-1. Anal calcd. for 
C24H23NO3 (373,44) C, 77.19; H, 6.21; N, 3.75; found: C, 77.15; H, 6.19; N, 3.71. 
2-(Naphthalen-1-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (107). Synthesized 
as 86, starting from 106, yield 99% as a yellow solid, mp 142-147 °C (from 
ethanol). 1H NMR (CDCl3): δ 3.60 (s, 6H), 3.74 (s, 3H), 4.03 (s, 2H), 6.26 (s, 2H), 
7.18-7.20 (m, 1H), 7.25-7.29 (m, 1H), 7.43-7.47 (m, 2H), 7.52-7.58 (m, 3H), 7.63-
7.65 (m, 1H), 7.84-7.86 (m, 1H), 7.94-7.96 (m, 2H), 8.19 ppm (broad s, disappeared 
on treatment with D2O, 1H). IR: ν 3317 cm-1. Anal calcd. for C28H25NO3 (423,50) C, 
79.41; H, 5.95; N, 3.31; found: C, 79.32; H, 5.84; N, 3.26. 
2-(Naphthalen-2-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (110). Synthesized 
as 86, starting from 109, yield 73% as a white solid, mp 138-140 °C (from ethanol). 
1H NMR (CDCl3): δ 3.73 (s, 6H), 3.83 (s, 3H), 4.29 (s, 2H), 6.52 (s, 2H), 7.13-7.17 
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(m, 1H), 7.24-7.28 (m, 1H), 7.46 (d, J = 8.1 Hz, 1H), 7.51-7.58 (m, 3H), 7.70 (dd, J 
=8.5 and 1.8 Hz, 1H), 7.82-7.94 (m, 3H), 7.99 (m, 1H), 8.30 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR: ν 3359 cm-1. Anal calcd. for 
C28H25NO3 (423,50) C, 79.41; H, 5.95; N, 3.31; found: C, 79.35; H, 5.86; N, 3.28.  
2-(1-(Phenylsulfonyl)-1H-pyrrol-3-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole 
(138). Synthesized as 86, starting from 137, yield 84% as a yellow solid, mp 176-
180 °C (from ethanol). 1H NMR (DMSOd6): δ 3.55 (s, 6H), 3.59 (s, 3H), 4.15 (s, 
2H), 6.46 (s, 2H), 6.81-6.82 (m, 1H), 6.97-6.99 (m, 1H), 7.06-7.08 (m, 1H), 7.32 (d, 
J = 8.0 Hz, 1H), 7.48-7.50 (m, 2H), 7.62-7.66 (m, 3H), 7.75-7.76 (m, 1H), 7.94-7.96 
(m, 2H), 11.16 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 3293 
cm-1. 
2-(1H-Pyrrol-3-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (83). Synthesized as 
82, starting from 138, yield 20% as a white solid, mp 195-197 °C (from ethanol). 1H 
NMR (DMSOd6): δ 3.59 (s, 3H), 3.61 (s, 6H), 4.14 (s, 2H), 6.48-6.49 (m, 1H), 6.53 
(s, 2H), 6.86-6.92 (m, 2H), 6.97-7.01 (m, 1H), 7.12-7.13 (m, 1H), 7.29 (d, J = 7.8 
Hz, 1H), 7.37 (d, J = 7.7 Hz, 1H), 10.88 (broad s, disappeared on treatment with 
D2O, 1H), 11.03 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 3242 
cm-1. Anal calcd. for C22H22N2O3 (362,42) C, 72.91; H, 6.12; N, 7.73; found: C, 
72.85; H, 6.09; N, 7.71. 
Methyl 5-bromo-3-(3,4,5-trimethoxyphenylthio)-1H-indole-2-carboxylate 
(60). A mixture of 124 (0.25 g, 0.001 mol), 3,4,5-bis(3,4,5-
trimethoxyphenyl)disulfide113 (0.55 g, 0.0014 mol) and sodium hydride (0.071 g, 
0.003 mol, 60% in mineral oil) in anhydrous DMF (2 mL) was placed into the MW 
cavity (closed vessel mode, Pmax = 250 PSI). MW irradiation of 150 W was used, 
the temperature being ramped from 25 °C to 110 °C. Once 110 °C was reached, 
taking about 1 min, the reaction mixture was held at this temperature for 2 min, 
while stirring, then cooled and quenched on crushed ice and extracted with ethyl 
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acetate. The organic layer was washed with brine, dried and filtered. Removal of the 
solvent gave crude 5-bromo-3-(3,4,5-trimethoxyphenylthio)-1H-indole-2-carboxylic 
acid (139), which was used without further purification. The crude acid (139) was 
dissolved in methanol (2.5 mL) and dichloromethane (10 mL) and treated with 
TMSDM (0.78 mL, 0.0015 mol, 2.0 M in hexane), while stirring at 25 °C for 30 min. 
Removal of the solvent gave a crude product that was purified by silica gel column 
chromatography (ethyl acetate:n-hexane = 1:1) to furnish 60 as a white solid (0.36 g, 
overall yield 79%), mp 160-162 °C (from ethanol). 1H NMR (CDCl3): δ 3.72 (s, 6H), 
3.81 (s, 3H), 3.98 (s, 3H), 6.48 (s, 2H), 7.33 (d, J = 9.3 Hz, 1H), 7.42 (dd, J = 1.9 
and 9.3 Hz, 1H), 7.72 (d, J = 1.9 Hz, 1H), 9.20 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR: ν 1680, 3296 cm-1. Anal calcd for C19H18BrNO5S 
(452.32) C, 50.55; H, 4.02; Br, 17.50; N, 3.10; found: C, 50.54; H, 4.01; Br, 17.50; 
N, 3.11. 
Ethyl 5-bromo-3-(3,4,5-trimethoxyphenylthio)-1H-indole-2-carboxylate (63). 
Was synthesized as 60, starting from 117 and 3,4,5-bis(3,4,5-
trimethoxyphenyl)disulfide.113 The crude acid (139) (0.5 g) was dissolved in 
absolute ethanol (1.7 mL) and treated with thionyl chloride (0.13 mL) at 0 °C under 
an Ar stream. The reaction mixture was stirred at 0 °C for 20 min, heated at 65 °C 
for 2 h, then cooled, and diluted with water and ethyl acetate. The organic layer was 
removed and washed with a saturated solution of sodium hydrogen carbonate and 
brine, dried and filtered. Removal of the solvent gave a crude product that was 
purified by silica gel column chromatography (ethyl acetate:n-hexane = 1:1) to give 
63 as a yellow solid (0.33 g, overall yield 70%), mp 150-152 °C (from ethanol). 1H 
NMR (CDCl3): δ 1.37 (t, J = 7.1 Hz, 3H), 3.72 (s, 6H), 3.80 (s, 3H), 4.43 (q, J = 7.8 
Hz, 2H), 6.48 (s, 2H), 7.33 (d, J = 8.7 Hz, 1H), 7.43-7.46 (m, 1H) 7.74-7.75 (m, 1H), 
9.23 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1672, 3299 cm-1. 
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Anal calcd for C20H20BrNO5S (452.32) C, 51.61; H, 4.33; Br, 16.97; N, 3.01; S, 6.87; 
found: C, 51.61; H, 4.32; Br, 16.97; N, 3.00; S, 6.87. 
General Procedure for the Synthesis of Compounds 79, 81, 84, 87, 90, 93, 96, 
99, 101, 103, 105 and 108. Example: 2-(1H-Pyrrol-2-yl)-3-[(3’,4’,5’-
trimethoxyphenyl)thio]-1H-indole (79). 2-(1H-Pyrrol-2-yl)-1H-indole138 (126) 
(0.25 g, 0.0014 mol) was carefully added to a suspension of sodium hydride (60% in 
mineral oil, 0.13 g, 0.0031 mol) in anhydrous DMF (2 mL) while stirring. After 10 
min, bis-(3,4,5-trimethoxyphenyl)disulfide113 (0.62 g, 0.0015 mol) was added, and 
the reaction mixture was placed into the MW cavity (closed vessel mode, Pmax = 
250 PSI). MW irradiation of 150 W was used, the temperature being ramped from 
25 °C to 110 °C while stirring. Once 110 °C was reached, taking about 1 min, the 
reaction mixture was held at this temperature for 2 min. The mixture was diluted 
with water and extracted with ethyl acetate. The organic layer was washed with 
brine and dried. Removal of the solvent gave a residue that was purified by column 
chromatography (alumina, chloroform as eluent) to furnish 79 (0.1 g, 19%), mp 215-
218 °C (from ethanol). 1H NMR (DMSO-d6): δ 3.52 (s, 6H), 3.55 (s, 3H), 6.18 (t, J 
= 2.9 Hz, 1H), 6,34 (s, 2H), 6.81 (d, J = 2.4 Hz, 1H), 6.96 (broad s, 1H), 7.04-7.08 
(m, 1H), 7.12-7.16 (m, 1H), 7.42 (d, J = 8.1 Hz, 2H), 11.11 (broad s, disappeared on 
treatment with D2O, 1H), 11.64 ppm (broad s, disappeared on treatment with D2O, 
1H). IR: ν 3329, 3422 cm-1. Anal calcd. for C21H20N2O3S (380.46) C, 66.29; H, 
5.30; N, 7.36; found: C, 66.03; H, 5.26; N, 7.15. 
2-(1H-Pyrrol-3-yl)-3-[(3’,4’,5’-trimethoxyphenyl)thio]-1H-indole (81). Was 
synthesized as 79, starting from 128, yield 10% as a brown solid, mp 200-204 °C 
(from ethanol). 1H NMR (DMSO-d6): δ 3.52 (s, 6H), 3.56 (s, 3H), 6.33 (s, 2H), 
6.75-6.77 (m, 1H), 6.84-6.86 (m, 1H), 7.00-7.04 (m, 1H), 7.08-7.12 (m, 1H), 7.39 
(d, J = 8.6 Hz, 2H), 7.48-7.50 (m, 1H), 11.11 (broad s, disappeared on treatment 
with D2O, 1H), 11.58 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 
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3358, 3390 cm-1. Anal calcd. for C21H20N2O3S (380.46) C, 66.29; H, 5.30; N, 7.36; 
found: C, 65.97; H, 5.12; N, 6.91. 
2-(Furan-2-yl)-3-[(3’,4’,5’-trimethoxyphenyl)thio]-1H-indole (84). Was 
synthesized as 79, starting from 118, yield 38% as a white solid, mp 180-184 °C 
(from ethanol). 1H NMR (CDCl3): δ 3.65 (s, 6H), 3.77 (s, 3H), 6.38 (s, 2H), 6.54 (q, 
J = 1.8 Hz, 1H), 7.17-7.20 (m, 1H), 7.24-7.25 (m, 2H), 7.44 (d, J = 8 Hz, 1H), 7.50 
(m, 1H), 7.67 (d, J = 8 Hz, 1H), 8.94 ppm (broad s, disappeared on treatment with 
D2O, 1H). IR: ν 3333 cm-1. Anal calcd. for C21H19NO4S (381.44) C, 66.12; H, 5.02; 
N, 3.67; found: C, 65.85; H, 4.98; N, 3.57. 
2-(Furan-3-yl)-3-[(3’,4’,5’-trimethoxyphenyl)thio]-1H-indole (87). Was 
synthesized as 79, starting from 130, yield 42% as a brown solid, mp 185-190 °C 
(from ethanol). 1H NMR (DMSO-d6): δ 3.64 (s, 6H), 3.76 (s, 3H), 6.34 (s, 2H), 6.87 
(m, 1H), 7.16 (t, J = 7.5 Hz, 1H), 7.22-7.26 (m, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.51 
(t, J = 1.6 Hz, 1H), 7.65 (dd, J = 0.6 and 7.8 Hz, 1H), 8.08-8.09 (m, 1H), 8.50 ppm 
(broad s, disappeared on treatment with D2O, 1H). IR: ν 3330 cm-1. Anal calcd. for 
C21H19NO4S (381.44) C, 66.12; H, 5.02; N, 3.67; found: C, 65.90; H, 4.92; N, 3.41. 
2-(Thiophen-2-yl)-3-[(3’,4’,5’-trimethoxyphenyl)thio]-1H-indole (90). Was 
synthesized as 79, starting from 133 yield 60% as a yellow solid, mp 195-198 °C 
(from ethanol). 1H NMR (DMSO-d6): δ 3.53 (s, 6H), 3.56 (s, 3H), 6.35 (s, 2H), 
7.09-7.13 (m, 1H), 7.19-7.24 (m, 2H), 7.47-7.49 (m, 2H), 7.65 (dd, J = 1.1 and 5.0 
Hz, 1H), 7.77 (dd, J = 1.1 and 3.7 Hz, 1H), 12.11 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR: ν 3317 cm-1. Anal calcd. for C21H19NO3S2 (397.51) C, 
63.45; H, 4.82; N, 3.52; found: C, 63.28; H, 4.78; N, 3.23. 
2-(Thiophen-3-yl)-3-[(3’,4’,5’-trimethoxyphenyl)thio]-1H-indole (93). Was 
synthesized as 79, starting from 134, yield 83% as a white solid, mp 220-225 °C 
(from ethanol). 1H NMR (CDCl3): δ 3.64 (s, 6H), 3.78 (s, 3H), 6.37 (s, 2H), 7.17-
7.21 (m, 1H), 7.25-7.29 (m, 1H), 7.42-7.44 (m, 2H), 7.64 (dd, J = 1.3 and 5.0 Hz, 
9. Experimental section 
 102
1H), 7.68 (d, J = 7.8 Hz, 1H), 7.85 (dd, J = 1.3 and 3.0 Hz, 1H), 8.62 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR: ν 3331 cm-1. Anal calcd. for 
C21H19NO3S2 (397.51) C, 63.45; H, 4.82; N, 3.52; found: C, 63.28; H, 4.75; N, 3.41.  
2-Phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (96). Was synthesized as 
79, starting from 2-phenyl-1H-indole, yield 3% as yellow solid, mp 158-160 °C 
(from ethanol). 1H NMR (CDCl3): δ 3.64 (s, 6H), 3.78 (s, 3H), 6.37 (s, 2H), 7.18-
7.22 (m, 1H), 7.27-7.30 (m, 2H), 7.41-7.50 (m, 3H), 7.69 (d, J = 7.9 Hz, 1H), 7.80-
7.82 (m, 2H), 8.56 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 
3329 cm-1. Anal calcd. for C23H21NO3S (391,48) C, 70.56; H, 5.41; N, 3.58; S, 8.19; 
found: C, 70.50; H, 5.37; N, 3.54; S, 8.12. 
2-(Pyridin-2-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (99). Was 
synthesized as 79, starting from 119, yield 25% as a yellow oil. 1H NMR (CDCl3): δ 
3.63 (s, 6H), 3.76 (s, 3H), 6.39 (s, 2H), 7.18 (t, J = 7.1 Hz, 1H), 7.24-7.27 (m, 2H), 
7.45 (d, J = 8.1 Hz, 1H), 7.70-7.77 (m, 2H), 8.63-8.64 (m, 1H), 8.73 (d, J = 8.1 Hz, 
1H), 10.23 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 2828, 2933, 
3003, 3056 cm-1. Anal calcd. for C22H20N2O3S (392.47) C, 67.33; H, 5.14; N, 7.14; 
S, 8.17; found: C, 67.28; H, 5.09; N, 7.11; S, 8.13. 
2-(Pyridin-3-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (101). Was 
synthesized as 79, starting from 120, yield 20% as a yellow solid, mp 188-193 °C 
(from ethanol). 1H NMR (CDCl3): δ 3.65 (s, 6H), 3.76 (s, 3H), 6.33 (s, 2H), 7.22 (m, 
1H), 7.31 (m, 1H), 7.37-7.41 (m 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.70 (d, J = 7.6 Hz, 
1H), 8.17 (dt, J = 1.7 and 8.0 Hz, 1H), 8.62 (m, 1H), 9.02 (m, 1H), 9.26 ppm (broad 
s, disappeared on treatment with D2O, 1H). IR: ν 2923, 3674 cm-1. Anal calcd. for 
C22H20N2O3S (392.47) C, 67.33; H, 5.14; N, 7.14; S, 8.17; found: C, 67.26; H, 5.07; 
N, 7.10; S, 8.11. 
2-(Pyridin-4-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (103). Was 
synthesized as 79, starting from 121, yield 60% as a yellow solid, mp 215-220 °C 
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(from ethanol). 1H NMR (DMSO-d6): δ 3.53 (s, 6H), 3.57 (s, 3H), 6.32 (s, 2H), 
7.14-7.18 (m, 1H), 7.27-7.31 (m, 1H), 7.53-7.57 (m, 2H), 7.92 (dd, J = 1.7 and 4.5 
Hz, 2H), 8.71 (dd, J = 1.6 and 4.5 Hz, 2H), 12.36 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR: ν 3320 cm-1. Anal calcd. for C22H20N2O3S (392.47) C, 
67.33; H, 5.14; N, 7.14; S, 8.17; found: C, 67.24; H, 5.06; N, 7.08; S, 8.08. 
2-(Naphthalen-1-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (105). Was 
synthesized as 79, starting from 136, yield 44% as a white solid, mp 227-230 °C 
(from ethanol). 1H NMR (CDCl3): δ 3.56 (s, 6H), 3.71 (s, 3H), 6.30 (s, 2H), 7.22-
7.26 (m, 1H), 7.29-7.33 (m, 1H), 7.39-7.55 (m, 4H), 7.61 (dd, J = 7.1 and 1.2 Hz, 
1H), 7.74-7.76 (m, 1H), 7.82-7.84 (m, 1H), 7.90-7.95 (m, 2H), 8.59 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR: ν 3229 cm-1. Anal calcd. for 
C27H23NO3S (441,54) C, 73.44; H, 5.25; N, 3.17; S, 7.26; found C, 73.37; H, 5.19; 
N, 3.11; S, 7.21. 
2-(Naphthalen-2-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (108). Was 
synthesized as 79, starting from 122, yield 44% as a white solid, mp 157-160 °C 
(from ethanol). 1H NMR (CDCl3): δ 3.65 (s, 6H), 3.79 (s, 3H), 6.42 (s, 2H), 7.22-
7.34 (m, 2H), 7.50-7.56 (m, 3H), 7.74-7.75 (m, 1H), 7.88-7.90 (m, 2H), 7.93-8.00 
(m, 2H), 8.25 (m, 1H), 8.71 ppm (broad s, disappeared on treatment with D2O, 1H). 
IR: ν 3318 cm-1. Anal calcd. for C27H23NO3S (441,54) C, 73.44; H, 5.25; N, 3.17; S, 
7.26; found C, 73.39; H, 5.21; N, 3.13; S, 7.23. 
Methyl 5-methoxy-3-(3,4,5-trimethoxyphenylsulfinyl)-1H-indole-2-
carboxylate (70). To a cold solution of 69113 (0.05 g, 0.00012 mol) in chloroform (5 
mL) was added 3-chloroperoxybenzoic acid (0.021 g, 0.00012 mol). The reaction 
mixture was stirred at 25 °C for 1.5 h, then diluted with water and extracted with 
chloroform. The organic layer was washed with brine, dried and filtered. Removal of 
the solvent gave a residue that was purified by silica gel column chromatography 
(ethyl acetate as eluent) to furnish 70 as a brown solid (0.05 g, yield 99%), mp 161-
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163 °C (from ethanol). 1H NMR (CDCl3): δ 3.74 (s, 3H), 3.84 (s, 9H), 3.85 (s, 3H), 
6.96 (d, J = 9.1 Hz, 1H), 7.10 (s, 2H), 7.31 (dd, J = 1.9 and 9.0 Hz, 1H), 7.42 (d, J = 
2.2 Hz, 1H), 9.37 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 1708, 
2831, 2933 cm-1. Anal calcd for C20H21NO7S (419.45) C, 57.26; H, 5.05; N, 3.34: S, 
7.63; found: C, 57.27; H, 5.06; N, 3.34: S, 7.63. 
Methyl 5-methoxy-3-(3,4,5-trimethoxyphenylsulfonyl)-1H-indole-2-
carboxylate (71). Was synthesized as 70, treating 69113 with 3-chloroperoxybenzoic 
acid (2 eq.), 96%, yellow solid, mp 176-180 °C (from ethanol). 1H NMR (DMSO-
d6): δ 3.33 (s, 3H), 3.82 (s, 6H), 3.83 (s, 3H), 3.93 (s, 3H), 7.04 (dd, J = 6.5 Hz, 1H), 
7.40 (s, 2H), 7.45 (d, J = 9.0 Hz, 1H), 7.59 (d, J = 2.4 Hz, 1H), 12.99 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR: ν 1701, 3298 cm-1. Anal calcd for 
C20H21NO8S (435.45) C, 55.15; H, 4.86; N, 3.22: S, 7.35; found: C, 55.14; H, 4.85; 
N, 3.22: S, 7.35. 
General Procedure for the Synthesis of Compounds 111-116. Example: Ethyl 
2-(2-(4-bromophenyl)hydrazono)propanoate (111). A mixture of 4-
bromophenylhydrazine hydrochloride (5.7 g, 0.0255 mol), ethyl pyruvate (2 g, 1.91 
mL, 0.017 mol) and sodium acetate (2.79 g, 0.034 mol) in ethanol (40 mL) was 
placed into the MW cavity (open vessel mode). MW irradiation at 250 W was used, 
the temperature being ramped from 25 °C to 100 °C. Once 100 °C was reached, 
taking about 2 min, the reaction mixture was held at this temperature for 5 min, 
while stirring. The reaction mixture was cooled at 0 °C, with stirring, and filtered to 
give 111, yield 90%, mp 142-144 °C (from ethanol). 1H NMR (CDCl3): δ 1.39 (t, J 
= 7.2 Hz, 3H), 2.12 (s, 3H), 4.33 (q, J = 7.1 Hz, 2H), 7.10 (d, J = 6.7 Hz, 2H), 7.40 
(d, J = 6.9 Hz, 2H), 7.64 ppm (broad s, disappeared on treatment with D2O, 1H). IR: 
ν 1576, 1675, 3290 cm-1. 
1-(1-(Furan-2-yl)ethylidene)-2-phenylhydrazine (112). Synthesized as 111, 
starting from phenylhydrazine hydrochloride and 2-acethylfurane, yield 96%, orange 
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solid, mp 79-84 °C (from ethanol). 1H NMR (DMSO-d6): δ 2.19 (s, 3H), 6.54-6.55 
(m, 1H), 6.70-6.71 (m, 1H), 6.74-6.77 (m, 1H), 7.18-7.23 (m, 4H), 7.68-7.69 (m, 
1H), 9.22 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 3342 cm-1. 
2-(1-(2-Phenylhydrazono)ethyl)pyridine (113). Synthesized as 111, starting 
from phenylhydrazine hydrochloride and 2-acethylpyridine, yield 90%, yellow solid, 
mp 150-153 °C (from ethanol). 1H NMR spectrum was identical to that reported in 
lit.139 
3-(1-(2-Phenylhydrazono)ethyl)pyridine (114). Synthesized as 111, starting 
from phenylhydrazine hydrochloride and 3-acethylpyridine, yield 85%, yellow solid, 
mp 140-143 °C (from ethanol). 1H NMR spectrum was identical to that reported in 
lit.140 
4-(1-(2-Phenylhydrazono)ethyl)pyridine (115). Synthesized as 111, starting 
from phenylhydrazine hydrochloride and 4-acethylpyridine, yield 90%, yellow solid, 
mp 143-145 °C (from ethanol). 1H NMR (CDCl3 ): δ 2.22 (s, 3H), 6.92-6.96 (m, 
1H), 7.20-7.22 (m, 2H), 7.30-7.34 (m, 2H), 7.58 (broad s, disappeared on treatment 
with D 2 O, 1H), 7.66 (dd, J = 1.6 and 4.6 Hz, 2H), 8.59 ppm (dd, J = 1.6 and 4.6 
Hz, 2H). IR: ν 3225 cm-1. 
1-(1-(Naphthalen-2-yl)ethylidene)-2-phenylhydrazine (116). Synthesized as 
111, starting from phenylhydrazine hydrochloride and 2-acethylnaphthalene, yield 
90%, white solid, mp 175-178 °C (from ethanol). 1H NMR (DMSO-d 6 ): δ 2.39 (s, 
3H), 6.67-6.80 (m, 1H), 7.23-7.32 (m, 4H), 7.47-7.54 (m, 2H), 7.87-7.90 (m, 2H), 
7.95-7.97 (m, 1H), 8.14 (m, 1H), 8.20 (dd, J = 1.8 and 8.7 Hz, 1H), 9.40 ppm (broad 
s, disappeared on treatment with D2O, 1H). IR: ν 3348 cm-1. 
General Procedure for the Synthesis of Compounds 117-122. Example: Ethyl 
5-bromo-1H-indole-2-carboxylate (117). 111 (35.15 g, 0.123 mol) was added in 
portions to PPA (350 g) preheated at 110 °C. The mixture was stirred at the same 
temperature for 30 min and then quenched with ice-water. The solid was filtered, 
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washed with water, dried and recrystallized from ethanol to give 117 as a brown 
solid (32.95 g, 60%), mp 160-161 °C. 1H NMR (CDCl3): δ 1.43 (t, J = 7.1 Hz, 3H), 
4.43 (q, J = 7.1 Hz, 2H), 7.15-7.16  (m, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.41 (dd, J = 
7.0 Hz, 1H), 7.84 (m, 1H), 9.98 ppm (broad s, disappeared on treatment with D2O, 
1H). IR: ν 1690, 3311 cm-1. 
2-(Furan-2-yl)-1H-indole (118). Synthesized as 117, starting from 112, yield 
55%, yellow solid, mp 123-125 °C (from ethanol). lit.141 120-123 °C. 
2-(Pyridin-2-yl)-1H-indole (119). Synthesized as 117, starting from 113, yield 
73%, white solid, mp 153-155 °C (from toluene). 1H NMR spectrum was identical to 
that reported in lit.139 
2-(Pyridin-3-yl)-1H-indole (120). Synthesized as 117, starting from 114, yield 
73%, yellow solid, mp 145-150 °C (from toluene). 1H NMR spectrum was identical 
to that reported in lit.140 
2-(Pyridin-4-yl)-1H-indole (121). Synthesized as 117, starting from 115, yield 
68%, brown solid, mp 210-215 °C (from toluene). 1H NMR spectrum was identical 
to that reported in lit.142 
2-(Naphthalen-2-yl)-1H-indole (122). Synthesized as 117, starting from 116, 
yield 45%, white solid, mp 200-203 °C (from cicloesane/ethanol). 1H NMR 
spectrum was identical to that reported in lit.143 
5-Bromo-1H-indole-2-carboxylic acid (123). A mixture of 117 (0.25 g, 0.001 
mol) in 3 N sodium hydroxide (2 mL) was placed into the MW cavity (closed vessel 
mode, Pmax = 250 PSI). MW irradiation at 150 W was used, the temperature being 
ramped from 25 °C to 110 °C. Once 110 °C was reached, taking about 1 min, the 
reaction mixture was held at this temperature for 2 min, while stirring. After cooling, 
the reaction mixture was made acidic with 3 N hydrochloric acid (pH = 2) and 
extracted with ethyl acetate; the organic layer was washed with brine, dried, filtered 
and evaporated to give 123 as a brown solid (0.23 g, 95%), mp 188 °C (from 
ethanol). 1H NMR (DMSO-d6): δ 7.05 (s, 1H), 7.32 (dd, J = 8.9 Hz, 1H), 7.39 (d, J 
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= 8.8 Hz, 1H), 7.85 (d, J = 2.1 Hz, 1H), 11.94 (broad s, disappeared on treatment 
with D2O, 1H), 12.61 ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 
1652, 2850, 3422 cm-1. 
Methyl 5-bromo-1H-indole-2-carboxylate (124). To a cold suspension of 123 
(3.4 g, 0.014 mol) in anhydrous methanol (13.4 mL) was added thionyl chloride (1.6 
mL) dropwise. The reaction mixture was stirred at the same temperature for 20 min, 
then heated at 65 °C for 2 h under an Ar stream, then cooled and diluted with water 
and ethyl acetate. The layers were separated, and the organic phase was washed with 
a saturated solution of sodium hydrogen carbonate and brine, dried, filtered and 
evaporated to give 124 as a white solid (3.43 g, 96%), mp 217-220 °C (from 
ethanol/cyclohexane), lit.144 211.8-213.6 °C. 
3-Bromo-1H-indole (125). A solution of bromine (2.77 g, 0.9 mL, 0.0173 mol) 
in DMF (15 mL) is dropped within a few minutes into a DMF solution (40 mL) of 1-
H-indole (2 g, 0.0171 mol) at 25 °C under stirring. The reaction mixture was poured 
into NaHCO3(SS) and extracted with CH2Cl2; organic layer was washed with brine, 
dried and filtered. The solution of 125 in CH2Cl2 was used for further reaction 
without evaporation of the solvent. 
2-(1H-Pyrrol-2-yl)-1H-indole (126). To a solution of 125 (3.35 g, 0.0171 mol) 
in CH2Cl2 (150 mL) was added 1H-pyrrole (1.15 g, 1.19 mL, 0.0171 mol) and 
CF3COOH (0.775 g, 0.52 mL, 0.007 mol). The reaction mixture was stirred at 25 °C 
for 20 minutes, made basic with acqueous ammonia and extracted with NaHCO3(SS); 
organic layer was washed with brine, dried and filtered. Removal of the solvent gave 
aresidue that was purified by alluminium oxide chromatography (ethyl acetate : n-
hexane = 2 : 8 as eluent) to furnish 126 as a white solid (0.55 g, 18%), mp 240-
245 °C (from ethanol). 1H NMR spectrum was identical to that reported in lit.145 
2-(2-Nitrophenyl)-1-[1-(phenylsulfonyl)-1H-pyrrol-3-yl]ethan-1-one (127). 
Oxalyl chloride (2.46 g, 1.64 mL, 0.019 mol) and a catalytic amount of anhydrous 
DMF were added at 0 °C to 2-(2-nitrophenyl)acetic acid (3.52 g, 0.019 mol) in 
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anhydrous 1,2-dichloroethane (88 mL) under an Ar stream. After 30 min, 1-
(phenylsulfonyl)-1H-pyrrole (4.04 g, 0.0019 mol) and anhydrous aluminum chloride 
(2.59 g, 0.0019 mol) were added. The reaction mixture was stirred at 0 °C for 25 
min, quenched on 1 N HCl/crushed ice and extracted with chloroform. The organic 
layer was washed with brine and dried. Removal of the solvent gave a residue that 
was purified by column chromatography (silica gel, acetone:n-hexane 1:2 as eluent) 
to furnish 127 as a yellow solid (0.7 g, 10%), mp 135 °C (from ethanol). 1H NMR 
(DMSO-d6): δ 4.45 (s, 2H), 6.41-6.43 (m, 1H), 7.25-7.30 (m, 2H), 7.45-7.60 (m, 5H), 
7.85-7.86 (m, 1H), 7.90-7.92 (m, 2H), 8.06 ppm (dd, J = 1.2 and 8.2 Hz, 1H). IR: ν 
1680 cm-1. 
2-[1-(Phenylsulfonyl)-1H-pyrrol-3-yl]-1H-indole (128). A mixture of 127 (0.25 
g, 0.0007 mol) and iron powder (0.27 g, 0.0049 ga) in glacial acetic acid (8 mL) was 
heated at 60 °C overnight. After cooling, the mixture was diluted with water while 
stirring and extracted with ethyl acetate. The organic layer was washed with brine 
and dried. Removal of the solvent gave a residue that was purified by column 
chromatography (silica gel, ethyl acetate:n-hexane 1:3 as eluent) to furnish 128 as a 
white solid (0.7 g, 10%), mp 180-185 °C (from ethanol). 1H NMR (DMSO-d6): δ 
6.66 (d, J = 1.4 Hz, 1H), 6.83-6.85 (m, 1H); 6.93-6.97 (m, 1H), 7.02-7.07 (m, 1H), 
7.31 (d, J = 8.0 Hz, 1H), 7.44-7.46 (m, 2H), 7.65-7.69 (m, 2H), 7.74-7.79 (m, 1H), 
7.84 (t, J = 1.9 Hz, 1H), 7.98-8.00 (m, 2H), 11.30 ppm (br s, 1H, disappeared on 
treatment with D2O). IR: ν 3407 cm-1. 
2-(Furan-3-yl)-1H-indole (130). A mixture of 2-iodo-1H-indole119 (129) (0.25 g, 
0.001 mol), furan-3-boronic acid pinacol ester (0.26 g, 0.00134 mol), potassium 
carbonate (0.18 g, 0.00134 mol), Pd(II) acetate (0.03 g, 0.000134 mol, 10% mol) in 
1-methyl-2-pyrrolidinone (2.3 mL) containing 0.18 mL of water was irradiated at 
200 W in the MW cavity (closed vessel mode, Pmax = 250 PSI), the temperature 
being ramped from 25 °C to 110 °C while stirring. Once 110 °C was reached, taking 
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about 2 min, the reaction mixture was held there for 15 min. After cooling, the 
mixture was diluted with water and extracted with ethyl acetate. The organic layer 
was washed with brine and dried. Removal of the solvent gave a residue that was 
purified by column chromatography (silica gel, ethyl acetate:n-hexane 1:5 as eluent) 
to furnish 130 as a white solid (0.18 g, 95%), mp 145-148 °C (from ethanol). 1H 
NMR (CDCl3): δ 6.61-6.62 (m, 1H), 6.70-6.71 (m, 1H), 7.09-7.19 (m, 2H), 7.36 (dd, 
J = 0.9 and 8.0 Hz, 1H), 7.50-7.52 (m, 1H), 7.58-7.60 (m, 1H), 7.75 (m, 1H), 8.10 
ppm (broad s, disappeared on treatment with D2O, 1H). IR: ν 3417 cm-1. 
2-Bromo-1-(thiophen-2-yl)ethan-1-one (131). A solution of bromine (2.53 g, 
0.82 mL, 0.0158 mol) in dichloromethane (8 mL) was added dropwise to 2-
acethylthiophene (2.0 g, 1.71 mL, 0.0158 mol) in the same solvent (10 mL). The 
reaction mixture was stirred at 25 °C for 1 h and neutralized with a saturated 
solution of sodium hydrogen carbonate. The organic layer was washed with brine 
and dried. Removal of the solvent gave a residue that was purified by column 
chromatography (silica gel, ethyl acetate:n-hexane 5:95 as eluent) to furnish 131 as a 
yellow oil (2.60 g, 80%).146 
2-Bromo-1-(thiophen-3-yl)ethanone (132). Synthesized as 131, starting from 3-
acethylthiophene, yield 57%, brown solid, mp 60-65 °C (from ethanol). 1H NMR 
(CDCl3): δ 4.34 (s, 2H), 7.35-.737 (m, 1H), 7.57 (dd, J = 1.3 and 5.1 Hz, 1H), 8.17-
8.18 ppm (m, 1H). IR: ν 1672 cm-1. 
2-(Thiophen-2-yl)-1H-indole (133). A mixture of 131 (0.5 g, 0.0024 mol) and 
aniline (0.4 g, 0.4 mL, 0.0041 mol) was kept at 25 °C for 3 h with occasional stirring, 
then a catalytic amount of  anhydrous DMF was added, and the reaction mixture was 
placed into the MW cavity (closed vessel mode, Pmax = 250 PSI). MW irradiation 
of 150 W was used, the temperature being ramped from 25 °C to 100 °C while 
stirring, with 100 °C being reached in about 1 min, and the reaction mixture was 
held at this temperature for an additional min. The mixture was diluted with 1 N HCl 
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and extracted with ethyl acetate. The organic layer was washed with brine and dried. 
Removal of the solvent gave a residue that was purified by column chromatography 
(silica gel, ethyl acetate:n-hexane 3:7 as eluent) to furnish 133 as a yellow solid 
(0.19 g, 40%), mp 175-180 °C (from cyclohexane). lit.147 167-168 °C (from hexane). 
2-(Thiophen-3-yl)-1H-indole (134). Synthesized as 133 starting from 132. Yield 
16% as a yellow solid, mp 210-215 °C (from cyclohexane). lit.148 212-214 °C. 
2-Bromo-1-(naphthalen-1-yl)ethanone (135). A solution of bromine (5.27 g, 
1.69 mL) in CH2Cl2 (17 mL) was added dropwise to a stirred solution of 1-
acetonaphthone (5.59 g, 5 mL, 0.033 mol) in the same solvent (20 mL). the reaction 
mixture was stirred at 25 °C for 1 h, then basified with NaHCO3SS and extracted 
with CH2Cl2; organic layer was washed with brine, dried and filtered. Removal of 
the solvent gave a residue that was purified by silica gel column chromatography 
(ethyl acetate:n-hexane 1:10 as eluent) to furnish 135 as a yellow oil (0.74 g, 90%). 
1H NMR spectrum was identical to that reported in lit.149 
2-(Naphthalen-1-yl)-1H-indole (136). A solution of aniline (1.24 g, 1.22 mL, 
0.0133 mol) in N,N-dimethylaniline (2.34 mL) was heated at 175 °C. 135 (1 g, 
0.0040 mol) was added and the reaction mixture was stirred for 15 minutes. After 
cooling 6 N HCl was added and the mixture was extracted with AcOEt; organic 
layer was washed with 6 N HCl, brine, dried and filtered. Removal of the solvent 
gave a residue that was purified by silica gel column chromatography (ethyl 
acetate:n-hexane 1:10 as eluent) to furnish 136 as a yellow solid (0.27 g, 28%), mp 
95-97 °C (from petroleum ether). 1H NMR spectrum was identical to that reported in 
lit.141 
2-(3,4,5-Trimethoxyphenyl)acetyl chloride. This compound was synthesized by 
treating a cold solution of 3,4,5-trimethoxyphenylacetic acid (0.25 g, 0.0011 mol) in 
anhydrous THF (5 mL) with oxalyl chloride (0.28 g, 0.19 mL, 0.0022 mol). 
Immediately afterwards, a catalytic amount (2 drops) of anhydrous DMF was added, 
and vigorous bubbling ensued. After 10 min, the reaction mixture was carefully 
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concentrated in vacuo to provide a viscous oil. Fresh anhydrous THF was added, and 
the solution was concentrated in vacuo again to furnish 2-(3,4,5-
trimethoxyphenyl)acetyl chloride (0.27 g, yellow oil), which was used without 
further purification. 
 
9.3 Molecular Modeling.  
All molecular modeling studies were performed on a MacPro dual 2.66GHz Xeon 
running Ubuntu 9. The tubulin structure was downloaded from the PDB data bank 
(http://www.rcsb.org/ - PDB ID: 1SA0,150 3KHC and 3KHE.151 Hydrogen atoms 
were added to the protein, using Molecular Operating Environment (MOE) 
2007.09,152 and minimized keeping all the heavy atoms fixed until a RMSD gradient 
of 0.05 kcal mol-1 Å-1 was reached. Ligand structures were built with MOE and 
minimized using the MMFF94x forcefield until a RMSD gradient of 0.05 kcal mol-1 
Å-1 was reached. The docking simulations were performed using FlexX,131 
Plants1.1132 and GLIDE.133 Molecular dynamics was performed with AMBER 9 
package153 on 1SA0 crystal structure. The minimized structure was solvated in a 
periodic octahedron simulation box using TIP3P water molecules, providing a 
minimum of 10 Å of water between the protein surface and any periodic box edge. 
The water molecules and sodium ions were energy minimized keeping the 
coordinates of the protein-ligand complex fixed (1000 cycle) then the whole system 
was minimized (5000 cycle). Following minimization, the entire system was heated 
to 298 K (10 ps). The production simulation was conducted at 298 K (time step 
0.002 psec) The periodic boundary condition was settled. The used cutoff was 8 Å. 
Shake bond length condition was used (ntc = 2). The polyphorylated compounds 
(GTP and GDP) were parametrized using orbital molecular calculation at the 
RHF/6-31+G* level.154 Compound was parametrized by Gamess155, 156 at the HF/6-
31+G* level. Trajectories analysis and the H-bonds rate of formation were carried 
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our by ptraj program,157 visual inspection were carried out by VMD.158 The images 
in the manuscript were created with Pymol.159 
 
9.4 Biology.  
Tubulin assembly. The reaction mixtures contained 0.8 M monosodium 
glutamate (pH 6.6 with hydrochloric acid in 2 M stock solution), 10 μM tubulin, and 
varying concentrations of drug. Following a 15 min preincubation at 30 °C, samples 
were chilled on ice, GTP to 0.4 mM was added, and turbidity development was 
followed at 350 nm in a temperature controlled recording spectrophotometer for 20 
min at 30 °C. Extent of reaction was measured.160  
[3H]Colchicine binding assay. The reaction mixtures contained 1.0 μM tubulin, 
5.0 μM [3H]colchicine, and 5.0 μM inhibitor and were incubated 10 min at 37 °C. 
Complete details were described previously.161 
Cell lines. Methodology for the evaluation of the growth of human MCF-7 breast 
carcinoma cells was previously described.161 Human HeLa cells (from carcinoma of 
the uterine cervix) and HCT116/chr3 cells (from colon carcinoma) were grown at 37 
°C in a humidified atmosphere containing 5% carbon dioxide in D-MEM (Gibco 
BRL, UK) supplemented with 10% fetal calf serum, 4 mM glutamine, 2 mM sodium 
pyruvate, 100 U/mL penicillin and 0.1 mg/mL streptomycin (all reagents were from 
Celbio, Italy). For the HCT116/chr3 cells, the medium also included 500 μg/mL of 
the selection compound G418 (Gibco). Cells were trypsinized when subconfluent 
and seeded in T75 flasks at a concentration of 105/mL. U937 (human monocytic 
leukemia cell line) and J774.1 cells (murine macrophage cell line) were cultured in 
RPMI 1640 medium containing 10% fetal calf serum, 50 μg/mL each of penicillin 
and streptomycin, and 2 mM glutamine. Human melanoma M14 cells and human 
embryonic kidney (HEK) 293 cells were grow at 37 °C in Dulbecco's modified 
Eagle's medium containing 10 mM glucose (DMEM-HG) supplemented with 10% 
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fetal calf serum and 50 μg/mL each of of penicillin and streptomycin. The P. 
tridactylis PtK2 cells, the A10 rat embryonic aortic smooth muscle cells, the human 
umbilical vein endothelial cells, and the human aortic smaooth muscle cells were 
obtained from the American Type Tissue Collection and grown as recommended by 
the supplier, except that a 5% CO2 atmosphere was used with all cells. 
Morphological analysis. Cells grown in T75 flasks and treated with 100 µM 57 
for 24 h were observed with an Olympus IX71 microscope and photographed with a 
Cool SNAPESES Photometric digital camera. 
Cell Viability Assay. MCF-7 cells. MCF-7 cell growth was quantitated by 
measuring cell protein with the dye sulforhodamine B after 48 h in the presence of 
various compound concentrations.161 
HeLa and HCT116/chr3 cells. Cells were seeded in 96 well-plates at a density of 
1x103 cells/100 μL well. Twenty-four hours later, cells were treated with the test 
compound (stock solution: 10 mM in DMSO, kept at room temperature in the dark) 
used at increasing concentrations (0.1-100 µM) for 24 h. Cells were harvested at the 
end of the treatment or washed with phosphate-buffered saline and incubated in 
drug-free medium for an additional 24 h. To rule out a possible effect of the solvent, 
parallel samples were incubated in complete medium containing 1% DMSO. At the 
end of the treatments, 20 μL of CellTiter96 Aqueous One Solution Reagent 
(Promega) was added to each well. The plates were then incubated for 4 h at 37 °C 
and analyzed with a microplate reader (Gio. De Vita, Roma, Italy) at 492 nm. 
Experiments were performed in quadruplicate and repeated three times. 
M14, HEK, U937 and J774.1 cells. Cell viability was determined using the 3-
[4,5-demethylthiazol-2,5-diphenyl-2H-tetrazolium bromide (MTT) colorimetric 
assay. The test is based on the ability of mitochondrial dehydrogenase to convert, in 
viable cells, the yellow MTT reagent into a soluble blue formazan dye. Cells were 
seeded into 96-well plates to a density of 105 cells/100 μL well. After 24 h of growth 
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to allow attachment to the wells, compounds were added at various concentrations 
(10, 30, 50, 100, 150 and 200 nM). After 24 or 48 h of growth and after removal of 
the culture medium, 100 μL/well of medium containing 1 mg/mL of MTT was 
added. Cell cultures were further incubated at 37 °C for 2 h in the dark. The MTT 
solution was then removed, and 100 μL DMSO was added to dissolve formazan 
crystals. Absorbance at 550 nm was measured using a plate reader. Experiments 
were performed in triplicate. As a control, 0.5% DMSO was added to untreated cells. 
Time-lapse microscopy. Effect of drug treatment on HEK and M14 cell 
morphology was determined by TLM using a Leica CTR6500 microscope. Images 
were captured every hour for a 48 h period. Ninty-six well plates were incubated 
under standard culture conditions and kept at 37 °C in a 5% carbon dioxide 
atmosphere for the observation period (up to 48 h).  
Yeast. S. cerevisiae yeast wild type strain BY4741 (Mat a his3Δ1 leu2Δ0 
met15Δ0 ura3Δ0) was used. Cells were grown at 28 °C in minimal medium (0.67% 
yeast nitrogen base without amino acids) containing 2% glucose (synthetic dextrose, 
SD) supplemented with 20 μg/μL of the appropriate nutritional supplements. 5x106 
cells/mL of a fresh exponential culture of the yeast were incubated for 18 h at 28 °C 
with the compound of interest at 20 μM. The cells were then centrifuged for 5 min at 
13,000 x g at 4 °C, washed twice with distilled water and resuspended in SD (1 mL). 
Cell suspensions (15 μL) were transferred in 60 μL of fresh SD medium, serially 
diluted ten-fold, incubated overnight at 28 °C and spotted onto YP plates (1% yeast 
extract, 2% peptone) supplemented with 2% glucose (YPD). The plates were 
incubated at 28 °C for three days before recording cell growth.  
Cell cultures and treatment. Cell lines were obtained from the American Tissue 
Culture Collection (ATCC), unless specified otherwise. Cells were grown in 
Dulbecco’s Modified Eagle medium (D-MEM) supplemented with 10% fetal bovine 
serum (FBS) at 37 °C with 5% CO2. In all experiments 300.000 cells were plated in 
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9 cm2 dishes and exposed to ATI compounds dissolved in DMSO (0.1% final 
concentration) at the indicated concentrations. Methodology for the evaluation of the 
growth of human MCF-7 breast carcinoma, OVCAR-8 and NCI/ADR-RES cells, 
obtained from the National Cancer Institute for drug screening, was previously 
described, except that cells were grown for 96 h for IC50 determinations.161 HeLa, 
PC3, HT29 and A549 cell lines were grown at 37 °C in D-MEM containing 10 mM 
glucose supplemented with 10% FBS, 100 units/mL each of penicillin and 
streptomycin and 2 mM glutamine. At the onset of each experiment, cells were 
placed in fresh medium and cultured in the presence of ATI compounds from 0.01 to 
25 μM. 231-MDA and A549 were cultured in DMEM supplemented with 10% FBS 
for 24, 48 and 72 h in a 96-well tissue culture plate at 37 °C and 5% CO2 in the 
absence or presence of different drug concentrations. The P. tridactylis PtK2 cells, 
the A10 rat embryonic aortic smooth muscle cells, the human umbilical vein 
endothelial cells, and the human aortic smooth muscle cells were obtained from 
ATCC and grown as recommended, except that a 5% CO2 atmosphere was used 
with all cells. Evaluation of growth inhibition of A2780wt, A2780-CIS and 
OVCAR-3 cell lines was performed as previously reported.162 
Cell Viability Assay. Cell viability was generally determined using the MTT 
colorimetric assay. Cells were seeded into 96-well plates to a density of 7x103/100 
μL well. After 24 h of growth to allow attachment to the wells, compounds were 
added at various concentrations (from 0.01 to 25 μM). After 48 h of growth and 
removal of the culture medium, 100 μL/well of medium containing 1 mg/mL of 
MTT was added. Cell cultures were further incubated at 37 °C for 2 h in the dark. 
The solution was then gently aspirated from each well and the formazan crystals 
within the cells were dissolved with 100 µL of DMSO. Optical densities were read 
at 550 nm using a Multiskan Spectrum Thermo Electron Corporation reader. Results 
were expressed as percentage relative to vehicle-treated control (0.5% DMSO was 
added to untreated cells), and IC50 values were determined by linear and polynomial 
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regression. Experiments were performed in triplicate. 231-MDA and A549 cells 
were plated at different cellular densities in order to test the drugs on logarithmic 
phase. The drugs were added after cell adhesion. On the day of the assay, 10 μL 
MTT (5 mg/mL) was added to each well, and cells were incubated for 2 h 
(37 °C ,5% CO2). When dark crystals appeared at the well bottom, culture medium 
was discarded, and ethanol (100 μL) was added to each well to solubilize the 
crystals, to yield a purple solution. Absorbance was read with an enzyme-linked 
immunosorbent assay (ELISA) reader at 570 nm. 
Immunofluoresence Assay. Cells to be processed for immunofluoresence were 
grown on sterile poly-L-lysine (SIAL) coated coverslips. After treatment, cells were 
either simultaneously fixed and permeabilized in MeOH for 6 min at -20 °C or, 
alternatively, first fixed in 3.7% paraformaldehyde (PFA) for 10 min followed by 
permeabilization in 0.1% Triton-X 100. The following antibodies were used: anti-β-
tubulin unconjugated (Sigma clone B5.1.2, 1:2000) or FITC-conjugated (Sigma, 
1:150); anti-γ-tubulin (Sigma, 1:1000); anti-processed caspase-3 (Cell Signalling 
Technology, 9661 1:500). Antibodies attached to their antigens were detected using 
secondary antibodies: anti-mouse Texas Red (Vector, TI-2000, 1:800), anti-mouse 
FITC (Jackson Immunoresearch Laboratories, 115-095-068; 1:200), anti-mouse 
AMCA (1:50), anti-rabbit FITC (Santa Cruz, sc-2090, 1:100), anti-rabbit Cy3 
(Jackson Immunoresearch Laboratories, 711-165-152, 1:1000). The DNA was 
stained with DAPI (Sigma, 0.05 µg/mL in H2O). Slides were finally mounted in 
Vectashield (Vector). 
Microscopy. Bright-field images of growing cells were taken under an inverted 
fluorescence microscope (Nikon TE 300) equipped with a DMX1200-type CCD 
(resolution 1280x1024 pixels) using ACT-1 software. Immunofluoresence images 
were obtained under an epifluorescence Olympus AX70 microscope equipped with a 
CCD camera (Diagnostic Instruments, Spot RT slider model 2.3.0) or a Nikon 
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Eclipse 90i microscope equipped with Qimaging camera and the NisElements AR 
3.1 software (Nikon). 
Flow Cytometry. Cell cycle distribution was analyzed after cell incubation with 
propidum idodide (Sigma). Apoptosis was analyzed after incubation of cells with 
annexin V-FITC (Immunofluorescence Science). Cell samples were analyzed in a 
Coulter Epics XL cytofluormeter (Beckman Coulter) equipped with EXPO 32 ADC 
software. Data for at least 10000 cells per sample were acquired. 
Western Blotting Analysis. Cells were plated in flasks (1 x 106 cells) and 
incubated with or without an ATI compound respectively. At the indicated times, 
cells were lysed using ice cold lysis buffer (50 mM Tris, 150 mM NaCl, 10 mM 
EDTA, 1% Triton) supplemented with protease inhibitor cocktail (antipain, bestatin, 
chymostatin, leupeptin, pepstatin, phosphoramidon, Pefabloc, EDTA and aprotinin, 
all from Boehringer,). Whole cell extracts were loaded on 8–12% sodium dodecyl 
sulfate polyacrylamide gels and electrophoresed, followed by blotting onto 
nitrocellulose membranes (BioRad). After membrane blocking with 5% (w/v) fat-
free milk powder, 0.1% Tween 20 in Tris buffered saline (TBS), it was incubated 
overnight at 4°C with specific antibodies at the concentrations indicated by the 
manufacturer (Cell Signaling Technology and Santa Cruz Biotechnology) in Tris-
buffered saline/Tween-20/5% milk . Following incubation with horseradish 
peroxidase-conjugated secondary antibody, bands were detected by enhanced 
chemiluminescence (ECL kit, Amersham). Each filter was reprobed with mouse 
monoclonal anti-tubulin antibody. The signal intensity of detected bands was 
quantified by NIH ImageJ 1.40 after normalization with actin. 
Metabolic Stability. Test compounds in duplicate at the final concentration of 1 
µM were dissolved in DMSO and pre-incubated for 10 min at 37 °C in potassium 
phosphate buffer pH 7.4, 3 mM MgCl2, with rat liver microsomes (Xenotech) at a 
final concentration of 0.5 mg/mL. After the pre-incubation period, reactions were 
started by adding the cofactors mixture (NADP, glucose-6-phosphate, glucose-6-
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phosphate dehydrogenase). Samples were taken at time 0, 5, 10, 15, 20 and 30 min 
and added to acetonitrile to stop the reaction and centrifuged. Supernatants were 
analyzed and quantified by LC-MS/MS. A control sample without cofactors was 
always added in order to check the stability of test compounds in the reaction 
mixtures. 7-Ethoxycoumarin was used as a reference standard. A fixed concentration 
of verapamil was added in every sample as an internal standard for LC-MS/MS. 
Samples were analyzed on a UPLC (Waters) interfaced with a Premiere XE Triple 
Quadrupole (Waters). Eluents were: phase A: 95% H2O, 5% acetonitrile + 0.1% 
HCOOH; phase B: 5% H2O, 95% acetonitrile + 0.1% HCOOH. Flow rate 0.6 
mL/min; column, Acquity BEH C18, 50 x 2.1 mm, 1.7 µm at 50 °C; injection 
volume, 5 µL. Samples were analyzed under the following conditions: electron 
spray ionization positive, desolvation temperature 450 °C, capillary 3.5 kV, 
extractor 5V. The percent of test compound remaining after a 30 min incubation 
period was calculated from the peak area relative to the area of the compound at 
time zero. 
Aqueous Solubility. The solubility of compound 81 was measured by means of 
the HTS. Samples are placed in a 96-well filter plate and incubated at room 
temperature for 90 min. The plate is then filtered, and solutions are analyzed by 
LC/MS-UV. 
In Vivo Drug Pharmacokinetic Studies. Pharmacokinetic experiments were 
performed using 4 week old male nude CD-1 mice (Charles River Laboratories). 
Animals were quarantined for approximately 1 week prior to the study. They were 
housed under standard conditions and had free access to water and standard 
laboratory rodent diet. Compound 81 was dissolved in a mixture 3% DMSO + 30% 
PEG400 + NaCl 0.9% at the concentration for the iv (rapid bolus) administration or 
a mixture 5% DMSO + 20% PEG400 + water for the oral (gavage) dose  (dose 
volume 5 ml/kg). Compound 81 were administered to mice either by iv or oral route, 
and blood samples were collected after different time points after dosing. Plasma 
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was separated immediately after blood sampling by centrifugation, plasma proteins 
were precipitated using Sirocco filtration plates or Oasis HLB elution plates 
according to the distributor instructions, and the plasma samples were kept frozen at 
−80 °C until submission to LC/MS/MS analysis. Sample analysis was performed on 
an Acquity UPLC using either a Acquity BEH C18 column (50 mm × 2.1 mm × 1.7 
μm) or a Acquity HSS T3 column (50 mm × 2.1 mm × 1.8 μm), coupled with a 
sample organizer and interfaced to a triple quadrupole Premiere XE (Waters). The 
mass spectrometer was operated using electrospray interface (ESI) with a capillary 
voltage of 3−4 kV, cone voltage of 25−52 V, source temperature of 115−120 °C, 
desolvation gas flow of 800 L/h, and desolvation temperature of 450−480 °C. 
Collision energy was optimized for each compound. LC−MS/MS analyses were 
carried out using a positive electrospray ionization (ESI(+)) interface in MRM 
(multiple reaction monitoring) mode. Pharmacokinetic parameters were calculated 
by a noncompartmental method using WinNolin 5.1 software (Pharsight). 
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